1
|
Davis EN, Doyle PC. An Assessment of Young Adults' Awareness and Knowledge Related to the Human Papillomavirus (HPV), Oropharyngeal Cancer, and the HPV Vaccine. Cancers (Basel) 2025; 17:344. [PMID: 39941716 PMCID: PMC11816247 DOI: 10.3390/cancers17030344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2024] [Revised: 01/08/2025] [Accepted: 01/16/2025] [Indexed: 02/16/2025] Open
Abstract
BACKGROUND/OBJECTIVES The human papillomavirus (HPV) is a prevalent sexually transmitted infection that is a known cause of morbidities such as genital warts and cancers of the cervix, anus, and oropharynx. Non-cervical HPV-related cancers have been a developing problem in North America, increasing in incidence by up to 225% in some instances over a span of two decades. METHODS This study investigated levels of awareness and knowledge of HPV, oropharyngeal cancer (OPC), and the HPV vaccine using a self-administered web-based survey designed specifically for this research. University students (n = 1005) aged 18-30 completed a 42-item questionnaire that included demographic information, awareness questions, and a series of "true/false/I don't know" knowledge questions. RESULTS The data gathered revealed that participants had relatively high levels of awareness. However, many respondents had significant gaps in their knowledge of HPV, OPC, and the HPV vaccine. Collectively, the data indicate that awareness and knowledge of HPV and the value of vaccination may place younger individuals at risk for HPV-related infections. CONCLUSIONS Although a relatively high level of awareness concerning HPV was observed, the gaps in knowledge suggest that further efforts are necessary to educate young adults. While all risk factors cannot be reduced, the present data may guide future efforts directed toward better education on HPV and related health concerns and associated risks.
Collapse
Affiliation(s)
- Eric N. Davis
- Laboratory for Quality of Life and Well-Being in Oncology, Rehabilitation Sciences, Western University, London, ON N6G 1H1, Canada
| | - Philip C. Doyle
- Otolaryngology Head and Neck Surgery, Division of Laryngology, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA
| |
Collapse
|
2
|
Sakr Y, Hamdy O, Eldeghedi M, Abdelaziz R, Med Sidi El Moctar E, Alharazin M, Awny S. Shifting Epidemiology Trends in Tongue Cancer: A Retrospective Cohort Study. Cancers (Basel) 2023; 15:5680. [PMID: 38067383 PMCID: PMC10705286 DOI: 10.3390/cancers15235680] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2023] [Revised: 11/05/2023] [Accepted: 11/17/2023] [Indexed: 04/26/2025] Open
Abstract
The tongue is the most common site for oral cavity carcinoma. It typically has male predominance. However, several studies have documented an increasing number of incidences among the younger population, with female predominance, which is unusual. In this study, we aimed to determine current trends in tongue cancer regarding age and gender. Data from 197 tongue cancer patients were extracted from The Oncology Center, Mansoura University (OCMU) database from 2006 to 2021. The patients were divided into two time periods: (2006-2013) and (2014-2021). We computed counts and proportions of tongue cancer for demographic and tumor characteristics. The data were analyzed using SPSS. Gender showed no statistically significant difference in both groups, while the percentages of diagnosed females were 52.7% and 52%, respectively. The percentages of males were 47.3% and 48%, p-value = 0.927. There was a statistically significant difference in the number of patients aged 20 to 39 years old and ≥60 years old in both periods. The p-values were 0.039 and 0.011, respectively. Although tongue cancer is typically more common in males, our results showed no significant difference in the gender of diagnosed patients. In addition, our results showed that the number of younger patients significantly increased in the period from 2014 to 2021. However, we encourage further investigations involving larger populations.
Collapse
Affiliation(s)
- Yara Sakr
- Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt; (Y.S.); (M.E.); (M.A.)
| | - Omar Hamdy
- Surgical Oncology Department, Oncology Center, Mansoura University, Mansoura 35516, Egypt;
| | - Maher Eldeghedi
- Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt; (Y.S.); (M.E.); (M.A.)
| | | | | | - Mohammed Alharazin
- Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt; (Y.S.); (M.E.); (M.A.)
| | - Shadi Awny
- Surgical Oncology Department, Oncology Center, Mansoura University, Mansoura 35516, Egypt;
| |
Collapse
|
3
|
Bloom JC, Kaufmann N, Koss S, Edwards HA, Perkins RB, Faden DL. Deciphering Knowledge and Opinions of Human Papillomavirus and Human Papillomavirus Vaccination for Facilitation of Point-of-Care Vaccination in Adults. JAMA Otolaryngol Head Neck Surg 2023; 149:870-877. [PMID: 37651109 PMCID: PMC10472267 DOI: 10.1001/jamaoto.2023.2073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2023] [Accepted: 06/11/2023] [Indexed: 09/01/2023]
Abstract
Importance Human papillomavirus (HPV) vaccination rates remain significantly below rates for other common childhood vaccines, which has implications for future rates of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). Objective To assess whether individuals who were aware of the association between HPV and OPSCC would be more likely to have been previously vaccinated. Design, Setting, and Participants This survey study included patients aged 18 to 45 years who sought routine outpatient care at the otolaryngology clinic at Boston Medical Center from September 1, 2020, to May 19, 2021. A survey (HPV-Associated Head and Neck Cancer Epidemiology, Awareness and Demographics) [HEAD]) composed of validated questions to assess patient knowledge of HPV and HPV vaccination and barriers to vaccination was delivered to participants. The survey was paired with a novel point-of-care vaccination program housed within an otolaryngology department. Main Outcomes and Measures The main outcome was prevalence of knowledge of the relationship between HPV infection and OPSCC based on survey responses. The association of knowledge of HPV-associated OPSCC with likelihood of having been vaccinated was assessed in the overall cohort and by demographic characteristics using multivariate logistic regression. Results Of 405 patients given the survey, 288 (71.1%) responded. Of these patients, 271 (94.1%) had surveys included; 158 (58.3%) were female, and median age was 29 years (IQR, 24-35 years). The baseline vaccination rate in the surveyed population was low (26.6%; n = 72) overall (10.6% among men [12 of 113]; 37.9% among women [60 of 158]). Few participants understood the relationship between HPV infection and OPSCC (63 of 271 [23.3%]) or that HPV-associated OPSCC is the most common HPV-associated cancer type (9 of 121 [7.4%]). Compared with men, women were more likely to have been previously vaccinated (odds ratio [OR], 6.5; 95% CI, 3.0-13.9), more aware that HPV causes cancer (OR, 3.7; 95% CI, 1.9-7.1), and more likely to have heard about HPV and HPV vaccination from their health care practitioner (OR, 2.6; 95% CI, 1.2-5.7). Knowledge of the relationship between HPV infection and cancer and between HPV and OPSCC was associated with increased likelihood of having been vaccinated (HPV and cancer: OR, 4.1 [95% CI, 1.8-9.5]; HPV and OPSCC: OR, 3.7 [95% CI, 1.8-7.6]). Among 156 unvaccinated participants, 12 of 98 men (12.2%) and 7 of 131 women (5.3%) received point-of-care vaccination. Conclusions Most participants in this survey study were unaware that HPV causes OPSCC. Understanding that HPV causes OPSCC was associated with increased likelihood of having been vaccinated. However, most patients surveyed were not informed of this relationship by their health care practitioners. Targeted education aimed at unvaccinated adults establishing the relationship between HPV infection and OPSCC, paired with point-of-care vaccination, may be an innovative strategy for increasing HPV vaccination rates in adults.
Collapse
Affiliation(s)
- Jacob C. Bloom
- Department of Otolaryngology–Head and Neck Surgery, Boston Medical Center, Boston, Massachusetts
| | - Nicole Kaufmann
- Department of Epidemiology, Harvard University School of Public Health, Boston, Massachusetts
| | - Shirley Koss
- Department of Otolaryngology–Head and Neck Surgery, Boston Medical Center, Boston, Massachusetts
| | - Heather A. Edwards
- Department of Otolaryngology–Head and Neck Surgery, Boston Medical Center, Boston, Massachusetts
| | - Rebecca B. Perkins
- Department of Obstetrics and Gynecology, Boston Medical Center, Boston, Massachusetts
| | - Daniel L. Faden
- Department of Otolaryngology–Head and Neck Surgery, Boston Medical Center, Boston, Massachusetts
- Department of Otolaryngology–Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts
- Mass Eye and Ear, Boston, Massachusetts
| |
Collapse
|
4
|
Kropotov MA, Yakovleva LP, Safarov DA, Saprina OA, Peshko DA, Khodos AV. Features of the clinical course and prognosis of tongue cancer in young women. HEAD AND NECK TUMORS (HNT) 2022. [DOI: 10.17650/2222-1468-2022-12-3-28-36] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Introduction. In recent times, changes in epidemiology of tongue cancer have been observed. morbidity among nonsmoking and non-abusing alcohol young women have been rising. Currently, etiology and pathogenesis of tumor development in this nosological group are unclear and require detailed analysis of epidemiologic and clinical data.Aim. To analyze the clinical material on the incidence of tongue cancer among young women (under 45 years old) over a 10-year period and assess the prevalence of this pathology in this group, the methods of treatment and reconstruction used, and determine the prognosis.Materials and methods. The study included 68 female patients with squamous cell carcinoma of the tongue who received treatment between 2010 and 2020. mean age was 36.8 years (between 18 and 45 years; median – 39 years). None of the patients had history of alcohol abuse or smoking. In 32 (47.1 %) patients, primary diagnosis was made at stages I–II, in 36 (52.9 %) at stages III–Iv.Results. In the last 10 years, a trend towards increased morbidity of tongue cancer among young women have been observed. In 2010, 2 cases of the disease were detected, in 2019–13, in 2020–14. mean follow-up duration was 40 months (median 32 months). Overall 5-year survival in this period was 72.5 ± 6.5 %, recurrence-free 5-years survival was 66.5 ± 6.6 %. Conclusion. Increase on tongue cancer morbidity among young non-smoking women is a new epidemiological trend worldwide. Etiological and pathogenetic factors of this trend have not been studied and require large multicenter studies for obtaining statistically significant results. Early medical resource utilization in this social group allows to perform adequate surgical intervention but requires the head and neck tumor specialist to pay attention to reconstructive surgery, quality and early patient rehabilitation allowing to preserve high quality of life, capacity for work and social activity.
Collapse
Affiliation(s)
- M. A. Kropotov
- N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
| | - L. P. Yakovleva
- A.S. Loginov Moscow Clinical Scientific Center of the Moscow Healthcare Department
| | - D. A. Safarov
- N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
| | - O. A. Saprina
- N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
| | - D. A. Peshko
- N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
| | - A. V. Khodos
- A.S. Loginov Moscow Clinical Scientific Center of the Moscow Healthcare Department
| |
Collapse
|
5
|
Badri P, Lai H, Ganatra S, Baracos V, Amin M. Factors Associated with Oral Cancerous and Precancerous Lesions in an Underserved Community: A Cross-Sectional Study. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2022; 19:1297. [PMID: 35162318 PMCID: PMC8835623 DOI: 10.3390/ijerph19031297] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 12/31/2021] [Revised: 01/20/2022] [Accepted: 01/21/2022] [Indexed: 11/16/2022]
Abstract
Street-involved people with limited access to regular healthcare have an increased risk of developing oral cancer and a lower survival rate. The objective of this study was to measure the prevalence of oral cancerous/precancerous lesions and determine their associated risk factors in a high-risk, underserved population. In this cross-sectional study, English-speaking adults aged 18 years and older living in a marginalized community in Edmonton were recruited from four non-profit charitable organizations. Data were collected through visual oral examinations and a questionnaire. Descriptive statistics, chi-squared tests, and logistic regressions were applied. In total, 322 participants with a mean (SD) age of 49.3 (13.5) years completed the study. Among them, 71.1% were male, 48.1% were aboriginal, and 88.2% were single. The prevalence of oral cancerous lesions was 2.4%, which was higher than the recorded prevalence in Canada (0.014-1.42: 10,000) and in Alberta (0.011-1.13: 10,000). The clinical examinations indicated that 176 (54.7%) participants had clinical inflammatory changes in their oral mucosa. There was a significant association between clinical inflammatory oral lesions and oral cancerous/precancerous lesions (p < 0.001). Simple logistic regression showed that the risk of the presence of oral cancerous/precancerous lesions was two times higher in participants living in a shelter or on the street than in those living alone (OR = 2.06; 95% CI: 1.15-3.82; p-value: 0.021). In the multiple logistic regression analysis, the risk of oral cancerous/precancerous lesions was 1.68 times higher in participants living in a shelter or on the street vs. living alone after accounting for multiple predictors (OR = 1.67; 95% CI: 1.19-2.37; p-value: 0.022). The results demonstrated a high prevalence of cancerous/precancerous lesions among the study participants, which was significantly associated with clinical inflammatory oral lesions. The evidence supports the need for developing oral cancer screening and oral health promotion strategies in underserved communities.
Collapse
Affiliation(s)
- Parvaneh Badri
- Faculty of Medicine and Dentistry, School of Dentistry, University of Alberta, Edmonton, AB T6G 1C9, Canada; (P.B.); (H.L.); (S.G.)
| | - Hollis Lai
- Faculty of Medicine and Dentistry, School of Dentistry, University of Alberta, Edmonton, AB T6G 1C9, Canada; (P.B.); (H.L.); (S.G.)
| | - Seema Ganatra
- Faculty of Medicine and Dentistry, School of Dentistry, University of Alberta, Edmonton, AB T6G 1C9, Canada; (P.B.); (H.L.); (S.G.)
| | - Vickie Baracos
- Department of Oncology, Cross Cancer Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 1Z2, Canada;
| | - Maryam Amin
- Faculty of Medicine and Dentistry, School of Dentistry, University of Alberta, Edmonton, AB T6G 1C9, Canada; (P.B.); (H.L.); (S.G.)
| |
Collapse
|
6
|
Daniel R, Lowry S, Pall H. State of the art vaccination strategies as primary prevention to reduce incidence of gastrointestinal cancers. J Gastrointest Oncol 2021; 12:S316-S323. [PMID: 34422396 DOI: 10.21037/jgo.2020.01.02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/23/2019] [Accepted: 12/31/2019] [Indexed: 11/06/2022] Open
Abstract
Immunizations have influenced the epidemiology of numerous gastrointestinal cancers. Human papillomavirus (HPV) is a common sexually transmitted infection (STI). Although most infections are transient and asymptomatic, persistent infections with oncogenic strains of HPV can progress to cervical, anal, penile, vaginal, vulvar, and oropharyngeal cancers. The introduction of HPV vaccinations has drastically reduced incidences of HPV-vaccine related infections and HPV related cervical cancers. The vaccine has proven to be safe and effective however, HPV vaccination rates have yet to reach target goals in the U.S. and many countries worldwide have not incorporated the vaccine into national immunization programs. The first successful nationwide vaccination program was employed against hepatitis B virus (HBV) in Taiwan in 1984 and demonstrated a statistically significant decrease in the incidence of hepatocellular carcinoma (HCC) in the 6 to 10 years after implementation of universal HBV vaccinations in infants. Twenty-year follow-up studies have continued to demonstrate statistically significant decreased rates of HBV related HCC among vaccinated populations. Despite the successful decrease in incidence of HBV-related HCC, efforts to create an effective prophylactic vaccination against hepatitis C virus (HCV) to prevent chronic HCV infection and its associated morbidity, including HCV-related HCC, have to date been unsuccessful.
Collapse
Affiliation(s)
- Rhea Daniel
- Department of Pediatrics, St. Christopher's Hospital for Children, Philadelphia, PA, USA
| | - Sarah Lowry
- Department of Pediatrics, St. Christopher's Hospital for Children, Philadelphia, PA, USA
| | - Harpreet Pall
- Department of Pediatrics, K. Hovnanian Children's Hospital/Hackensack Meridian Health School of Medicine at Seton Hall University, Nutley, NJ, USA
| |
Collapse
|
7
|
[Oral and pharyngeal cancer: incidence, mortality, and survival in Germany]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2021; 64:941-950. [PMID: 34212206 PMCID: PMC8316202 DOI: 10.1007/s00103-021-03368-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Accepted: 06/01/2021] [Indexed: 12/24/2022]
Abstract
Hintergrund Die Gruppe der Lippen‑, Mundhöhlen- und Pharynxkarzinome (ICD-10: C00–C14) beschreibt eine heterogene Gruppe bösartiger Tumoren, deren Inzidenz, Mortalität und Überleben sich nach Entität stark unterscheiden. Ziel der Arbeit Diese Arbeit gibt eine detaillierte Übersicht epidemiologischer Maßzahlen für diese Tumorentitäten unter Berücksichtigung der Heterogenität bezüglich Alter, Geschlecht, Lokalisation und Stadium. Material und Methoden Inzidenz- und Mortalitätsdaten für Deutschland für die Jahre 1999–2016 wurden aus der interaktiven Datenbank des Zentrums für Krebsregisterdaten (ZfKD) extrahiert. Alters- und Stadienverteilungen und altersstandardisiertes relatives 5‑Jahres-Überleben wurden auf dem gepoolten ZfKD-Datensatz (Diagnosejahre 1999–2017) berechnet. Ergebnisse Im Jahr 2016 lagen die Inzidenz und Mortalität für alle Entitäten insgesamt bei 17,6 bzw. 7,0 pro 100.000 Männern und 6,5 bzw. 1,8 pro 100.000 Frauen. Das relative 5‑Jahres-Überleben für 2015–2017 lag bei 53 % bzw. 63 %. Es zeigten sich deutliche Unterschiede in der Überlebensrate und in der Alters- und Stadienverteilung zwischen den Entitäten. Im zeitlichen Verlauf zeigte sich ein Anstieg des Alters bei Diagnose, insbesondere bei Männern, aber keine Veränderung in der Stadienverteilung. Trotzdem stieg das relative 5‑Jahres-Überleben zwischen 1999–2002 und 2013–2017 von 45 % (Männer) bzw. 59 % (Frauen) auf 52 % bzw. 63 %. Diskussion Die starke Heterogenität der untersuchten Tumoren verdeutlicht die Notwendigkeit einer nach Geschlechtern und Lokalisationen getrennten Betrachtung für eine aussagekräftige Interpretation der epidemiologischen Kennzahlen. Mit Ausbau der klinischen Krebsregistrierung werden in Zukunft zusätzliche Analysen unter Einbezug weiterer wichtiger klinischer Faktoren möglich sein. Zusatzmaterial online Zusätzliche Informationen sind in der Online-Version dieses Artikels (10.1007/s00103-021-03368-z) enthalten.
Collapse
|
8
|
Aragón N, Ordoñez D, Urrea MF, Holguín J, Collazos P, García LS, Osorio MC, Barreto JM, Bravo LE. Head and neck cancer in Cali, Colombia: Population-based study. Community Dent Oral Epidemiol 2021; 50:292-299. [PMID: 34105170 PMCID: PMC8651828 DOI: 10.1111/cdoe.12671] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Revised: 05/11/2021] [Accepted: 05/18/2021] [Indexed: 12/14/2022]
Abstract
INTRODUCTION Head and neck cancer (HNC) is the seventh most common type of cancer in the world. In Latin America, data on HCN are limited by the scarcity of population-based cancer registries. OBJECTIVE To describe survival and changes in the time trends of incidence and mortality rates of HCN with data from the Cali Cancer Population Registry (Colombia) during 1962-2018. METHOD Males and females of any age residing in Cali were included. The trends in incidence rates (1962-2016) and mortality (1984-2018) were analysed by calculating the mean annual percentage change (APC). Five-year net survival was estimated for the four 5-year periods of 1996-2015 using the Pohar-Perme method. RESULTS During 1962-2015, 5,110 new cases of HNC were recorded: 1,506 in the larynx, 1,377 in the oral cavity, 487 in the nose and paranasal sinuses, 643 in the oropharynx, 603 in the salivary glands and 360 in Naso-Hypopharynx region. The incidence rates of HNC decreased significantly at all subsites, except in those associated with the human papillomavirus. Between 1984 and 2018, there were 1,941 deaths attributed to HNC, and the mortality rate decreased significantly. The 5-year age-standardized net survival was 43.2% in 1996-2000, remained stable during the following decade, and for 2011-2015 it was 50.9%. CONCLUSION The incidence and mortality of HNC in Cali decreased significantly during the study period in both sexes.
Collapse
Affiliation(s)
- Natalia Aragón
- School of Dentistry, Universidad del Valle, Cali, Colombia
| | - Dora Ordoñez
- School of Dentistry, Universidad del Valle, Cali, Colombia
| | | | - Jorge Holguín
- Department of Otorhinolaryngology, Universidad del Valle, Cali, Colombia
| | - Paola Collazos
- Department of Pathology, Universidad del Valle, Cali, Colombia
| | | | - María C Osorio
- Department of Otorhinolaryngology, Universidad del Valle, Cali, Colombia
| | - José M Barreto
- Department of Otorhinolaryngology, Universidad del Valle, Cali, Colombia
| | | |
Collapse
|
9
|
Noel CW, Sutradhar R, Li Q, Forner D, Hallet J, Cheung M, Singh S, Coburn NG, Eskander A. Association of Immigration Status and Chinese and South Asian Ethnicity With Incidence of Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg 2021; 146:1125-1135. [PMID: 33151263 DOI: 10.1001/jamaoto.2020.4197] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Importance Head and neck cancer (HNC) incidence varies worldwide, although it remains one of the most common cancers among those of East Asian and South Asian ethnicity. Objective To determine the association of Chinese and South Asian ethnicity, independent of immigration status, with HNC incidence. Design, Setting, and Participants This was a retrospective population-based matched cohort study that examined data collected between 1994 and 2017 in Ontario, Canada. Data were analyzed between July 2019 and March 2020. Individuals who immigrated to Canada between 1985 and 2017 were classified as immigrants, whereas Canadian-born individuals and those who immigrated prior to 1985 were classified as long-standing residents. Two separate, matched cohorts were created: an immigration cohort, consisting of immigrants and long-standing residents hard matched on age and sex, and an ethnicity cohort, where participants were further matched on ethnicity (Chinese, South Asian, or non-Chinese/non-South Asian). Exposures Chinese ethnicity, South Asian ethnicity, and immigration status. Main Outcomes and Measures Patients newly diagnosed with primary HNC were captured in both the immigration and the ethnicity cohorts. Cause-specific hazard models were used to estimate the association of immigration status and ethnicity with HNC incidence. Results In the immigration cohort, 3 328 434 matched individuals (mean [SD] age, 36.73 [13.46] years; 52.8% female) were followed, across which 3173 unique HNC diagnoses were made. The hazard ratio (HR) for a new diagnosis of oropharynx cancer was lower in immigrants compared with long-standing residents (HR, 0.26 [95% CI, 0.22-0.31]). In the ethnicity cohort, after adjusting for age, sex, rurality, and deprivation, the rate of HNC diagnosis was higher for Chinese individuals (HR, 1.49 [95% CI, 1.36-1.64]) and South Asian individuals (HR, 1.29 [95% CI, 1.14-1.45]), although it was lower for immigrants (HR, 0.48 [95% CI, 0.44-0.52]) when compared with non-Chinese and non-South Asian individuals. There was no difference in the incidence of nasopharynx cancer when comparing immigrants and long-standing residents of Chinese ethnicity. Conclusions and Relevance Immigration status appears to offer a protective effect against a diagnosis of HNC. Chinese and South Asian ethnic groups may experience higher HNC incidence when compared with the general Ontario population.
Collapse
Affiliation(s)
- Christopher W Noel
- Department of Otolaryngology-Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada.,Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.,Institute for Clinical and Evaluative Sciences, Toronto, Ontario, Canada
| | - Rinku Sutradhar
- Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.,Institute for Clinical and Evaluative Sciences, Toronto, Ontario, Canada
| | - Qing Li
- Institute for Clinical and Evaluative Sciences, Toronto, Ontario, Canada
| | - David Forner
- Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.,Division of Otolaryngology-Head and Neck Surgery, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Julie Hallet
- Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.,Institute for Clinical and Evaluative Sciences, Toronto, Ontario, Canada.,Department of Surgical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Matthew Cheung
- Department of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Simron Singh
- Department of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Natalie G Coburn
- Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.,Institute for Clinical and Evaluative Sciences, Toronto, Ontario, Canada.,Department of Surgical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Antoine Eskander
- Department of Otolaryngology-Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada.,Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.,Institute for Clinical and Evaluative Sciences, Toronto, Ontario, Canada.,Department of Surgical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| |
Collapse
|
10
|
Jung YS, Seok J, Hong S, Ryu CH, Ryu J, Jung KW. The emergence of oral cavity cancer and the stabilization of oropharyngeal cancer: Recent contrasting epidemics in the South Korean population. Cancer 2021; 127:1638-1647. [PMID: 33595858 DOI: 10.1002/cncr.33434] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Revised: 12/18/2020] [Accepted: 12/21/2020] [Indexed: 01/15/2023]
Abstract
BACKGROUND By analyzing the recent epidemiologic trajectory of head and neck squamous cell carcinoma (HNSCC) in South Korea, we tracked 2 findings that have been reported recently in other countries: the stabilization of human papillomavirus (HPV)-related HNSCC incidence and the acceleration of oral cavity cancer incidence. METHODS We analyzed data from the comprehensive population-based Korean Central Cancer Registry for the period 1999 to 2017. The age-standardized incidence rate (ASR), annual percent change (APC), and relative survival were calculated. RESULTS The ASR of total HNSCC decreased from 1999 to 2017 (APC, -0.2 [95% CI, -0.3 to -0.0]), as did the ASR of HPV-unrelated HNSCC (APC, -0.6 [95% CI, -0.8 to -0.5]); however, the ASR of HPV-related HNSCC increased (APC, 2.9 [95% CI, 2.5 to 3.2]). The rapidly increasing incidence of tonsil squamous cell carcinoma, which was the main subsite of HPV-related HNSCC, stabilized after 2011 (APC pre-2011, 6.8 [95% CI, 5.0 to 8.3]; APC post-2011, 1.6 [95% CI, -2.1 to 5.5]), and the difference was significant (P = .017). In contrast, oral cavity cancer incidence demonstrated the only increase among HPV-unrelated subsites, with the increase occurring after 2006 (APC pre-2006, 1.6 [95% CI, 0.3 to 2.8]; APC post-2006, 2.8 [95% CI, 2.2 to 3.5]); the main cause of this change was an increase in the ASR of tongue cancer. CONCLUSION This study demonstrates the recent stabilization of tonsil cancer incidence and the contrasting increase in oral cavity cancer incidence, unlike other HPV-unrelated cancers. These trends require further surveillance and understanding in terms of tumor biology and prevention.
Collapse
Affiliation(s)
- Yuh-Seog Jung
- Department of Otorhinolaryngology-Head and Neck Surgery, National Cancer Center, Goyang, Republic of Korea
| | - Jungirl Seok
- Department of Otorhinolaryngology-Head and Neck Surgery, National Cancer Center, Goyang, Republic of Korea
| | - Seri Hong
- The Korea Central Cancer Registry, National Cancer Center, Goyang, Republic of Korea.,Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center, Goyang, Republic of Korea
| | - Chang Hwan Ryu
- Department of Otorhinolaryngology-Head and Neck Surgery, National Cancer Center, Goyang, Republic of Korea
| | - Junsun Ryu
- Department of Otorhinolaryngology-Head and Neck Surgery, National Cancer Center, Goyang, Republic of Korea
| | - Kyu-Won Jung
- The Korea Central Cancer Registry, National Cancer Center, Goyang, Republic of Korea.,Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center, Goyang, Republic of Korea
| |
Collapse
|
11
|
Huang K, Ni G, Ma B, Chen S, Luan Y, Wang T, Walton S, Frazer I, Liu X, Pan X. Importance of human papillomavirus infection in squamous cell carcinomas of the tongue in Guangdong Province, China. J Int Med Res 2020; 48:300060519897187. [PMID: 31948314 PMCID: PMC7113701 DOI: 10.1177/0300060519897187] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Objective Methods Results Conclusion
Collapse
Affiliation(s)
- Kunsong Huang
- The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China
| | - Guoying Ni
- The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.,Genecology Research Centre, University of the Sunshine Coast, Maroochydore DC, QLD, Australia
| | - Bowei Ma
- The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China
| | - Shu Chen
- Cancer Research Institute, Foshan First People's Hospital, Foshan, Guangdong, China
| | - Yi Luan
- Cancer Research Institute, Foshan First People's Hospital, Foshan, Guangdong, China
| | - Tianfang Wang
- Genecology Research Centre, University of the Sunshine Coast, Maroochydore DC, QLD, Australia
| | - Shelley Walton
- Inflammation and Healing Research Cluster, School of Health and Sport Sciences, University of Sunshine Coast, Maroochydore DC, QLD, Australia
| | - Ian Frazer
- Translational Research Institute, University of Queensland, Brisbane, QLD, Australia
| | - Xiaosong Liu
- The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.,Inflammation and Healing Research Cluster, School of Health and Sport Sciences, University of Sunshine Coast, Maroochydore DC, QLD, Australia.,Cancer Research Institute, Foshan First People's Hospital, Foshan, Guangdong, China
| | - Xuan Pan
- The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China
| |
Collapse
|
12
|
Influences of Semaphorin 3A Expression on Clinicopathological Features, Human Papillomavirus Status, and Prognosis in Oropharyngeal Carcinoma. Microorganisms 2020; 8:microorganisms8091286. [PMID: 32842711 PMCID: PMC7565979 DOI: 10.3390/microorganisms8091286] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2020] [Revised: 08/19/2020] [Accepted: 08/20/2020] [Indexed: 12/13/2022] Open
Abstract
Human papillomavirus (HPV) infection is now identified as a major etiologic factor for oropharyngeal cancer (OPC), and HPV positivity is well established better prognostic marker in OPC. Now, predictable markers for the prognosis of the patients who are stratified by HPV has been investigated in. Semaphorin 3A (SEMA3A) is a well-known axon guidance molecule in the nervous system. It is also known as a tumor suppressor in various cancers. In the present study, we examined the relationships between SEMA3A and clinicopathologic features, especially HPV status, and neoangiogenesis, and its prognostic significance for OPC patients. Thirty-two OPC patients and 17 normal patients were analyzed for SEMA3A expression by immunohistochemical analysis. We also analyzed 22 OPC specimens for CD34 expression as a marker of neoangiogenesis. SEMA3A was significantly downregulated in OPC compared with chronic tonsillitis tissues (p = 0.005). SEMA3A expression was negatively correlated with CD34 expression (r = −0.466, p = 0.033). Moreover, the higher SEMA3A expression cohort showed better survival than the lower SEMA3A expression cohort regardless of HPV status (p = 0.035). These results suggest that SEMA3A expression is a prognostic marker for survival regardless of HPV status and is associated with anti-angiogenesis in OPC.
Collapse
|
13
|
The emerging risk of oropharyngeal and oral cavity cancer in HPV-related subsites in young people in Brazil. PLoS One 2020; 15:e0232871. [PMID: 32407339 PMCID: PMC7224475 DOI: 10.1371/journal.pone.0232871] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2020] [Accepted: 04/23/2020] [Indexed: 02/06/2023] Open
Abstract
Human papillomavirus (HPV) is responsible for the rise in the incidence of cancer in the oropharynx, tonsils, and base of the tongue (i.e., HPV-related subsites). HPV triggered the changes in the epidemiology of oropharyngeal and oral cavity cancer (OPC/OCC) in Asia, Europe, North America, and Oceania. Hence, the incidence of cancer in HPV-related subsites is augmenting, while that in other HPV-unrelated subsites is decreasing. In South America, although the incidence of HPV-positive tumors has gradually increased, there is an atypically low prevalence of HPV in people with OPC/OCC. To clarify whether this dramatic shift in incidence trends also occurred in this population, we estimated the burden of HPV on the incidence trends of OPCs/OCCs in São Paulo city in Brazil. In this population-based study, we categorized OPCs/OCCs by HPV-related and HPV-unrelated subsites. We used Poisson regression to assess the age-standardized incidence rates (ASRs) stratified by sex and age groups, as well as to examine the age-period-cohort effects. There were 15,391 cases of OPCs/OCCs diagnosed in HPV-related (n = 5,898; 38.3%) and HPV-unrelated (n = 9,493; 61.7%) subsites. Overall, the ASRs decreased for most subsites, for both sexes and for all age groups, except for HPV-related OPC/OCC in young males and females, which increased by 3.8% and 8.6% per year, respectively. In the birth-cohort-effect analysis, we identified an increasing risk for HPV-related OPC/OCC in both sexes in recent birth cohorts; however, this risk was sharply decreased in HPV-unrelated subsites. Our data demonstrate an emerging risk for HPV-related OPC/OCC in young people, which supports prophylactic HPV vaccination in this group.
Collapse
|
14
|
Lekoane KMB, Kuupiel D, Mashamba-Thompson TP, Ginindza TG. The interplay of HIV and human papillomavirus-related cancers in sub-Saharan Africa: scoping review. Syst Rev 2020; 9:88. [PMID: 32321580 PMCID: PMC7178989 DOI: 10.1186/s13643-020-01354-1] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/27/2018] [Accepted: 04/08/2020] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND People living with HIV (PLHIV) are at a high risk of developing HPV-related cancers. HPV-related malignancies occur frequently and/or are high among PLHIV, with cervical cancer as a designated AIDS-defining condition. We aimed to explore the evidence on the interplay of HIV and HPV-related cancers in sub-Saharan Africa (SSA). METHODS The scoping review was guided by Arksey and O'Malley's framework. We searched for literature from the following databases: PubMed; World Health Organization (WHO) Library; Science Direct; Google Scholar and EBSCOhost (Academic search complete, Health Source: Nursing/Academic Edition, CINAHL). Studies reporting on evidence HIV and HPV-related cancers interplay in SSA were eligible for inclusion in this review. The Mixed Methods Appraisal Tool (MMAT) tool was used to assess the risk of bias of the included studies. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was used for reporting the search results. Thematic analysis used to reveal the emerging themes from the included studies. RESULTS A total of 74 potentially eligible articles were screened. Of these, nine (7 reviews, 1 transversal case controls, and 1 quantitative study) were eligible for data extraction. The studies reported about a total of 16,351 participants in different settings. The nine included studies showed evidence of cervical cancer among HIV-infected women and distribution of HPV infection and cervical abnormalities among HIV-positive individuals. In the four studies generalizing about HIV and anal cancer, only one reported about HPV. Two studies generally reported about HIV and head and neck cancers and one reported about interaction of HIV with vaginal cancer, vulvar cancer, and penile cancer, respectively. CONCLUSION HIV positivity is associated with increased prevalence of HPV infection on different anatomic sites, which will result in increased burden of HPV-related cancers among PLHIV. Furthermore, primary studies with robust study designs aimed at investigating the risk developing HPV-related cancers among PLHIV are recommended. Systematic review registration: PROSPERO CRD42017062403.
Collapse
Affiliation(s)
- Kabelo Matjie Bridget Lekoane
- Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa
| | - Desmond Kuupiel
- Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa
- Department of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa
| | - Tivani P. Mashamba-Thompson
- Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa
| | - Themba G. Ginindza
- Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa
| |
Collapse
|
15
|
Snietura M, Brewczynski A, Kopec A, Rutkowski T. [Infiltrates of M2-Like Tumour-Associated Macrophages Are Adverse Prognostic Factor in Patients with Human Papillomavirus-Negative but Not in Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma]. Pathobiology 2020; 87:75-86. [PMID: 32036360 DOI: 10.1159/000505522] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2019] [Accepted: 12/17/2019] [Indexed: 11/19/2022] Open
Abstract
INTRODUCTION Human papillomavirus with a high oncogenic potential (HR-HPV) is responsible for more than a half of squamous cell carcinomas of the oropharynx. The HR-HPV-dependent cases of this tumour have a better prognosis compared to the HR-HPV-negative cases, despite the usually more advanced disease at the time of diagnosis. In addition to genetic and epigenetic factors, the causes of this more favourable course of the disease are also seen in the participation of the tumour microenvironment, including the patient's immune system. Macrophages are one of the most important elements of the immunocompetent cells landscape that make up the tumour microenvironment. Traditionally, they are divided into 2 groups: inflammatory macrophages with the M1 phenotype and tumour-associated macrophages known as M2 phenotype macrophages. OBJECTIVE The aim of this study was to investigate the impact of the macrophage infiltrates intensity of the M1/M2 and M2 phenotype separately on the clinical outcome of patients with squamous cell carcinoma of the oropharynx (OPSCC), taking into account the HR-HPV status of tumours. METHODS The study involved 85 patients with OPSCC in which HR-HPV status in tumour tissue was determined using a double-check algorithm including the detection of viral DNA by RT-PCR method with subsequent confirmation of its biological activity by immunohistochemical demonstrating the P16INK4A protein overexpression. In each of the groups formed on the basis of HR-HPV status, macrophages were discriminated using CD68 and CD163 proteins as markers of pan-macrophage and M2 phenotype. The intensity of infiltrates was quantified by means of computer-assisted analysis in digital images of whole slides (virtual slides) separately in tumour tissue and stroma. RESULTS In HPV-positive patients, significantly more intense infiltration of both M1/M2 and M2 macrophages was found in the tumour stroma compared to HPV-negative patients. The infiltrates from both types of macrophages in the tumour tissue were less intense and did not differ between these groups. Intensive infiltration of CD68+ macrophages in the tumour front was associated with higher rate of nodal failures and a shorter nodal control in both HR-HPV groups. In the group of HR-HPV-negative patients, heavy infiltration of CD163+ macrophages was associated with significantly shorter: loco-regional control (LRC), metastasis-free survival and overall survival (OS). These parameters and prognosis in patients with scanty CD163+ infiltration were similar to favourable outcomes in HR-HPV-positive patients. The relative risk of local-regional recurrence, distant metastases and disease-related death in HR-HPV-negative patients with intense CD163+ infiltrates was, respectively, 4.7, 5.4 and 5.7 compared to patients with scanty infiltrates. CONCLUSIONS Tumours with a positive HR-HPV status demonstrate intense infiltrations of total pool M1/M2 and M2 macrophages. In the group of HPV-negative patients, intensive M1/M2 macrophage infiltrates correlate with higher risk of nodal failures, and intensive M2 infiltrates are an adverse prognostic factor for LRC, metastasis-free survival and OS.
Collapse
Affiliation(s)
- Miroslaw Snietura
- Tumour Pathology Department, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland,
| | - Adam Brewczynski
- Radiation and Clinical Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland
| | - Agnieszka Kopec
- Tumour Pathology Department, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland
| | - Tomasz Rutkowski
- Radiation and Clinical Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland
| |
Collapse
|
16
|
Dance Dance "Cultural" Revolution: Tailoring a Physical Activity Intervention for South Asian Children. J Immigr Minor Health 2019; 22:291-299. [PMID: 31399904 DOI: 10.1007/s10903-019-00921-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
In Canada, South Asian (SA) children are more likely to be overweight and physically inactive than non-SAs. This study uses a mixed-methods embedded design to investigate factors associated with physical activity (PA) among SAs, and develops a culturally-relevant exercise intervention for SA children ages 8-11. Twenty-eight (28) participants including children, parents, principals, teachers, and Bhangra instructors across four elementary schools in Surrey, BC participated in semi-structured interviews and a self-report survey. Using the immersion/crystallization approach, four major themes were identified: (1) awareness of the importance and benefits of PA, (2) discrepancy between expectations and actual opportunities for PA in the school-setting, (3) sub-optimal conditions for PA at school and home, and (4) intervention characteristics conducive for promoting exercise in SA children. Competing demands and lack of opportunities posed as prominent obstacles. To address these barriers, a culturally-appealing exercise intervention may offer a viable approach to motivate SA children to exercise.
Collapse
|
17
|
Lekoane KMB, Kuupiel D, Mashamba-Thompson TP, Ginindza TG. Evidence on the prevalence, incidence, mortality and trends of human papilloma virus-associated cancers in sub-Saharan Africa: systematic scoping review. BMC Cancer 2019; 19:563. [PMID: 31185951 PMCID: PMC6558783 DOI: 10.1186/s12885-019-5781-3] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2018] [Accepted: 05/31/2019] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Human papilloma virus (HPV) associated cervical cancer remains a global concern particular, in Sub-Saharan Africa (SSA) where the impact is felt most. Evidence show that many other cancers such as vaginal, anal, oropharyngeal, penile are because of persistent infection with HPV especially, high-risk types. AIM We mapped evidence on the incidence, prevalence, mortality, and the trends of human papillomavirus-related cancers in SSA. METHODS A comprehensive literature search was conducted from several databases including PubMed, Google scholar, Science Direct, and CINAHL and MEDLINE via EBSCOhost as well as World Health Organization website for grey literature. Studies reporting HPV-related cancers in SSA outcomes including prevalence, incidence, mortality, and trends were included in this study. The risk of bias of the included studies were assessed using the mixed methods appraisal tool version 2011. We employed PRISMA (preferred reporting items for systematic reviews and meta-analyses) to report the search results. Thematic analysis used to reveal the emerging themes from the included studies. RESULTS Seventy-four (74) studies were retrieved at full article screening, eight of them (six reviews, and two quantitative study) were eligible for data extraction. The degree of agreement between the two independent reviewers following full article screening, was 86.49% agreement versus 64.57% likely by chance which constituted moderate to significant agreement (Kappa statistic = 0.62, p-value< 0.05). Of the eight included studies, four (50%) studies generalized about SSA with no country of interest; two (25%) studies were conducted in Nigeria; one (12.5%) reported about Uganda, Zambia, Guinea, Malawi Tanzania, Mali, Mozambique, Zimbabwe; and one (12.5%) reported about Ethiopia, Senegal, Zimbabwe and Uganda. These eight included studies reported evidence on more than one outcome of interest. Four studies reported about the prevalence of HPV-related cancers, seven studies reported about the incidence, four studies reported about mortality, and four studies reported about the trends of HPV-related cancers. CONCLUSION This study observation highlighted a gap of knowledge regarding the epidemiological data on the recent HPV prevalence in SSA, which will have a potential impact in determining the distribution of HPV on different body sites (cervix, penis, vagina, vulva, anus and oropharynx). Ongoing research projects are recommended in SSA to enhance the value of HPV, and HPV-associated cancers epidemiological data to inform strategies or/and policies on prevention, diagnosis, and treatment of HPV-related conditions.
Collapse
Affiliation(s)
- Kabelo M. B. Lekoane
- Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, 2nd Floor George Campbell Building, Howard College Campus, Durban, 4001 South Africa
| | - Desmond Kuupiel
- Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, 2nd Floor George Campbell Building, Howard College Campus, Durban, 4001 South Africa
- Research for Sustainable Development, Sunyani, Ghana
| | - Tivani P. Mashamba-Thompson
- Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, 2nd Floor George Campbell Building, Howard College Campus, Durban, 4001 South Africa
| | - Themba G. Ginindza
- Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, 2nd Floor George Campbell Building, Howard College Campus, Durban, 4001 South Africa
| |
Collapse
|
18
|
Paderno A, Morello R, Piazza C. Tongue carcinoma in young adults: a review of the literature. ACTA ACUST UNITED AC 2019; 38:175-180. [PMID: 29984792 DOI: 10.14639/0392-100x-1932] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2017] [Accepted: 01/09/2018] [Indexed: 12/15/2022]
Abstract
SUMMARY A recent reduction in the number of smoke-related tumours has been observed thanks to the diffusion of anti-tobacco campaigns carried out in the majority of developed countries. Nevertheless, as demonstrated by recent global epidemiologic studies, squamous cell carcinoma of the mobile tongue appears to be progressively increasing in incidence, particularly among young adults and especially in females. The driving mechanism responsible for such changes is still to be precisely defined. Several genetic studies have compared the mutational pattern of tongue squamous cell carcinoma in young adults to that of more elderly patients, without identifying significant differences that may help in better characterising this subgroup of subjects. Tongue squamous cell carcinomas in young adults have been historically considered as particularly aggressive clinical entities, with a high risk of loco-regional relapse, survival rates inferior to those of the general head and neck cancer group and need for a more aggressive therapy. However, considering the most recent studies, prognostic results in this patient group are heterogeneous and it is not possible to confirm this tendency. Thus, it is not justified to embrace different therapeutic approaches according to patient age. Eventually, an additional element to consider when examining young subjects affected by tongue cancer is the possibility of genetic predisposition. Alterations affecting pathways involved in DNA repair, surveillance of genetic stability or regulation of cellular growth may determine an increased likelihood of developing head and neck cancers.
Collapse
Affiliation(s)
- A Paderno
- Department of Otolaryngology, Head and Neck Surgery, University of Brescia, Italy
| | - R Morello
- Department of Otolaryngology, Head and Neck Surgery, University of Brescia, Italy
| | - C Piazza
- Department of Otolaryngology, Head and Neck Surgery, Fondazione IRCCS, Istituto Nazionale dei Tumori di Milano, University of Milan, Italy
| |
Collapse
|
19
|
Forner D, Rigby MH, Wilke D, Taylor SM, Lamond N. Risk stratification models in human papillomavirus-associated oropharyngeal squamous cell carcinoma: the Nova Scotia distribution. J Otolaryngol Head Neck Surg 2019; 48:3. [PMID: 30642398 PMCID: PMC6332880 DOI: 10.1186/s40463-019-0325-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2018] [Accepted: 01/07/2019] [Indexed: 11/10/2022] Open
Abstract
OBJECTIVE The incidence of oropharyngeal squamous cell carcinoma is increasing with a growing proportion of diagnoses associated with human papillomavirus (p16 + OSCC), which generally confers a favorable prognosis. For these reasons, novel risk stratification models specific to the p16 + OSCC population have recently been proposed to guide future research on treatment de-intensification for appropriate patients. This study aimed to quantify patient risk distribution using multiple published risk models and investigate the hypothesis that the local p16 + OSCC population includes a smaller proportion of low-risk patients due to a high prevalence of concurrent tobacco exposure. METHODS A retrospective cohort study was performed including patients diagnosed with p16 + OSCC in Nova Scotia between 2011 and 2015. Patient identification was obtained through the CCNS registry and an institutional database. Exclusion criteria included HPV negative status, second primary cases, incomplete data availability, and local recurrence cases. RESULTS Following exclusion, 117 patients met study criteria. The majority had small primary tumors (70.9% ≤ T2) and advanced nodal status on presentation (60.7% ≥ N2b). Most patients had a positive smoking history (62.4%), with 53.0% of patients having a pack-year history greater than 10 pack-years. In four of the five risk stratification models, the majority of the study population fell into the lowest risk category. The risk stratification distribution of our local population was similar to the populations used to validate the published models, with the largest single category difference being 13.3% (range - 12.3 to + 13.3%). CONCLUSIONS This is the first study to compare multiple currently published risk stratification models to a local population and address the uncertainty of risk stratification in the Nova Scotian p16 + OSCC population. Despite a high prevalence of concurrent tobacco exposure, the study population was found to be overall low risk, with similar risk compared to model validation populations.
Collapse
Affiliation(s)
- David Forner
- Division of Otolaryngology - Head & Neck Surgery, Department of Surgery, Dalhousie University, Halifax, Nova Scotia, Canada. .,Division of Medical Oncology, Department of Internal Medicine, QEII - Bethune Building, Dalhousie University, Suite 470, 1276 South Park Street, Halifax, Nova Scotia, B3H 2Y9, Canada.
| | - Matthew H Rigby
- Division of Otolaryngology - Head & Neck Surgery, Department of Surgery, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Derek Wilke
- Department of Radiation Oncology, Dalhousie, Halifax, Nova Scotia, Canada
| | - S Mark Taylor
- Division of Otolaryngology - Head & Neck Surgery, Department of Surgery, Dalhousie University, Halifax, Nova Scotia, Canada
| | - Nathan Lamond
- Division of Medical Oncology, Department of Internal Medicine, QEII - Bethune Building, Dalhousie University, Suite 470, 1276 South Park Street, Halifax, Nova Scotia, B3H 2Y9, Canada
| |
Collapse
|
20
|
Monteiro LS, Antunes L, Santos LL, Bento MJ, Warnakulasuriya S. Survival probabilities and trends for lip, oral cavity and oropharynx cancers in Northern Portugal in the period 2000-2009. Ecancermedicalscience 2018; 12:855. [PMID: 30093917 PMCID: PMC6070366 DOI: 10.3332/ecancer.2018.855] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2018] [Indexed: 12/15/2022] Open
Abstract
Background Oral cancer represents a serious public health problem worldwide. Our aim was to analyse the survival probabilities and trends of patients presenting with lip, oral cavity and oropharynx cancers, who were residents in the north of Portugal. Methods Using cancer-registry data, we conducted a population-based study of lip, oral cavity and oropharynx cancers diagnosed in the period 2000-2009, among residents in the north of Portugal. Net survival was estimated using the Pohar-Perme estimator. Excess hazard ratios (for gender, age group, tumour location, stage, residence area and period of diagnosis) were estimated using flexible parametric models. Results A total of 2,947 cases (79.5% males) were included of which 18.5% were located on the lip, 56.2% in the oral cavity and 25.3% in the oropharynx. A large proportion of patients were diagnosed in stages III and IV (18.6% and 48.7%, respectively). The 5-year net survival (5yr-NS) for all three cancer sites together was 46% (95%CI 44-48), being 88% (95%CI 83-94), 41% (95%CI 38-43) and 27% (95%CI 23-30) for lip, oral cavity and oropharynx cancer, respectively. The 5yr-NS stratified by tumour stage was 84% (95%CI 78-90) for stage I, 69% (95%CI 63-76) for stage II, 42% (95%CI 37-47) for stage III and 19% (95%CI 16-21) for stage IV. When comparing the periods 2000-4 and 2005-9, no overall improvements in survival were observed. However, when analysed by stage, a significant reduction in the adjusted excess mortality was observed for stages II (p = 0.021) and III (p < 0.001). Conclusion More than half of the oral cavity and oropharynx cancers were diagnosed in advanced stages of the disease, having a low survival probability. Improvements in survival in the first decade of this century were limited to stages II and III, which were the result of changes in hospital cancer care practices.
Collapse
Affiliation(s)
- Luís Silva Monteiro
- Department of Medicine and Oral Surgery, Cancer Research Group, IINFACTS, Instituto Universitário de Ciências da Saúde Norte-CESPU, Paredes 4585-116, Portugal
| | - Luís Antunes
- Cancer Epidemiology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto 4200-072, Portugal
| | - Lúcio Lara Santos
- Experimental Pathology and Therapeutics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto, Porto 4200-072, Portugal.,Department of Surgical Oncology, Portuguese Oncology Institute of Porto, Porto 4200-072 Portugal
| | - Maria José Bento
- Cancer Epidemiology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto 4200-072, Portugal
| | - Saman Warnakulasuriya
- King's College London and WHO Collaborating Centre for Oral Cancer, London SE5 9RW, UK
| |
Collapse
|
21
|
Forner D, Wilke D, Rigby MH, Croul S, Mishra A, Massoud E, Clarke DB, Lamond N. Cavernous sinus involvement in human papillomavirus associated oropharyngeal squamous cell carcinoma: case report of an atypical site of distant metastasis. J Otolaryngol Head Neck Surg 2018; 47:32. [PMID: 29743120 PMCID: PMC5941456 DOI: 10.1186/s40463-018-0280-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2017] [Accepted: 04/29/2018] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND HPV-associated OSCC (HPV-OSCC) has been determined to be a distinct disease entity from non-HPV associated OSCC. Patients affected by HPV-OSCC generally have a more favourable prognosis, with improved rates of locoregional control and survival compared with their non-HPV counterparts. Despite this, HPV-OSCC has a similar rate of distant metastases. Interestingly, recent evidence has emerged that demonstrates more frequent atypical metastasis patterns when compared to non-HPV associated disease. To the best of our knowledge, this report describes the first case of a confirmed HPV-OSCC with distant metastasis to the cavernous sinus. CASE PRESENTATION A 62-year-old non-smoking male presented to the head and neck oncology clinic with a five-month history of enlarging right neck mass causing neck pain, dysphagia, and dysphonia. HPV-associated base of tongue squamous cell carcinoma (cT4aN2c) was diagnosed, and he was treated with primary chemoradiation. Shortly after treatment, he presented with progressive bilateral cranial nerve palsies including left cranial nerve III and right cranial nerve VI involvement. Imaging identified masses in the left cavernous sinus with extension of tumor into the sella and in the right cavernous sinus at the level of Dorello's canal. Endoscopic Image Guided Transsphenoidal biopsy of the left sellar mass confirmed distant metastases from the previously treated HPV-OSCC primary to the cavernous sinus. The patient was palliated with carboplatin and paclitaxel. CONCLUSION The presented report is the first documented case of confirmed HPV-associated oropharyngeal squamous cell carcinoma metastasizing to the cavernous sinus, and the only HPV confirmed head and neck cancer case to present with metastasis to the cavernous sinus and limited extracranial disease. This case demonstrates the importance of recognizing presentations of atypical metastasis that are possible in HPV-associated oropharyngeal cancer. Given the rarity of metastasis to this region, vigilance in follow up is instrumental in early identification and treatment for these patients.
Collapse
Affiliation(s)
- David Forner
- Division of Otolaryngology - Head & Neck Surgery, Department of Surgery, Queen Elizabeth Health Science Center, Dalhousie University, Third Floor Dickson Building, Victoria General Site, 820 University Avenue, Halifax, B3H 1Y9, NS, Canada.
| | - Derek Wilke
- Department of Radiation Oncology, Nova Scotia Cancer Centre, Dalhousie University, Dickson Building, Room 2200, main floor, 5820 University Avenue, Halifax, B3H 1V7, NS, Canada
| | - Matthew H Rigby
- Division of Otolaryngology - Head & Neck Surgery, Department of Surgery, Queen Elizabeth Health Science Center, Dalhousie University, Third Floor Dickson Building, Victoria General Site, 820 University Avenue, Halifax, B3H 1Y9, NS, Canada
| | - Sidney Croul
- Department of Pathology & Laboratory Medicine, Division of Anatomical Pathology, Dalhousie University, Room 635-B, 6th Floor, DJ Mackenzie Building, 5788 University Avenue, Halifax, B3H 2Y9, NS, Canada
| | - Anuradha Mishra
- Department of Ophthalmology & Visual Sciences, Dalhousie University, 1278 Tower Road, Room 2035, 2W Victoria, Halifax, B3H 2Y9, NS, Canada
| | - Emad Massoud
- Division of Otolaryngology - Head & Neck Surgery, Department of Surgery, Queen Elizabeth Health Science Center, Dalhousie University, Third Floor Dickson Building, Victoria General Site, 820 University Avenue, Halifax, B3H 1Y9, NS, Canada.,Division of Neurosurgery, Department of Surgery, QEII Health Sciences Centre, Dalhousie University, 1796 Summer Street, Suite 3806, Halifax, B3H 3A7, NS, Canada
| | - David B Clarke
- Division of Otolaryngology - Head & Neck Surgery, Department of Surgery, Queen Elizabeth Health Science Center, Dalhousie University, Third Floor Dickson Building, Victoria General Site, 820 University Avenue, Halifax, B3H 1Y9, NS, Canada.,Department of Ophthalmology & Visual Sciences, Dalhousie University, 1278 Tower Road, Room 2035, 2W Victoria, Halifax, B3H 2Y9, NS, Canada.,Division of Neurosurgery, Department of Surgery, QEII Health Sciences Centre, Dalhousie University, 1796 Summer Street, Suite 3806, Halifax, B3H 3A7, NS, Canada
| | - Nathan Lamond
- Division of Medical Oncology, Department of Medicine, Dalhousie University, QEII - Bethune Building, Suite 470 Bethune Building, 1276 South Park Street, Halifax, B3H 2Y9, NS, Canada
| |
Collapse
|
22
|
Gilde J, Song B, Masroor F, Darbinian JA, Ritterman Weintraub ML, Salazar J, Yang E, Gurushanthaiah D, Wang KH. The diagnostic pathway of oropharyngeal squamous cell carcinoma in a large U.S. healthcare system. Laryngoscope 2017; 128:1867-1873. [DOI: 10.1002/lary.27038] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2017] [Revised: 10/20/2017] [Accepted: 11/08/2017] [Indexed: 12/17/2022]
Affiliation(s)
- Jason Gilde
- Department of Otolaryngology–Head and Neck Surgery, Kaiser Permanente Oakland Medical CenterOakland California U.S.A
| | - Brian Song
- Department of Otolaryngology–Head and Neck Surgery, Kaiser Permanente Oakland Medical CenterOakland California U.S.A
| | - Farzad Masroor
- Department of Otolaryngology–Head and Neck Surgery, Kaiser Permanente Oakland Medical CenterOakland California U.S.A
| | - Jeanne A. Darbinian
- Department of Otolaryngology–Head and Neck Surgery, Kaiser Permanente Oakland Medical CenterOakland California U.S.A
| | | | - James Salazar
- Department of Otolaryngology–Head and Neck Surgery, Kaiser Permanente Oakland Medical CenterOakland California U.S.A
| | - Eleanor Yang
- Department of Otolaryngology–Head and Neck Surgery, Kaiser Permanente Oakland Medical CenterOakland California U.S.A
| | - Deepak Gurushanthaiah
- Department of Otolaryngology–Head and Neck Surgery, Kaiser Permanente Oakland Medical CenterOakland California U.S.A
| | - Kevin H. Wang
- Department of Otolaryngology–Head and Neck Surgery, Kaiser Permanente Oakland Medical CenterOakland California U.S.A
| |
Collapse
|
23
|
Zamoiski RD, Yanik E, Gibson TM, Cahoon EK, Madeleine MM, Lynch CF, Gustafson S, Goodman MT, Skeans M, Israni AK, Engels EA, Morton LM. Risk of Second Malignancies in Solid Organ Transplant Recipients Who Develop Keratinocyte Cancers. Cancer Res 2017; 77:4196-4203. [PMID: 28615224 PMCID: PMC5540772 DOI: 10.1158/0008-5472.can-16-3291] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2016] [Revised: 03/06/2017] [Accepted: 06/05/2017] [Indexed: 01/07/2023]
Abstract
Solid organ transplant recipients have increased risk for developing keratinocyte cancers, including cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), in part as a result of immunosuppressive medications administered to prevent graft rejection. In the general population, keratinocyte cancers are associated with increased risks of subsequent malignancy, however, the risk in organ transplant populations has not been evaluated. We addressed this question by linking the U.S. Scientific Registry of Transplant Recipients, which includes data on keratinocyte cancer occurrence, with 15 state cancer registries. Risk of developing malignancies after keratinocyte cancer was assessed among 118,440 Caucasian solid organ transplant recipients using multivariate Cox regression models. Cutaneous SCC occurrence (n = 6,169) was associated with 1.44-fold increased risk [95% confidence interval (CI), 1.31-1.59] for developing later malignancies. Risks were particularly elevated for non-cutaneous SCC, including those of the oral cavity/pharynx (HR, 5.60; 95% CI, 4.18-7.50) and lung (HR, 1.66; 95% CI, 1.16-2.31). Cutaneous SCC was also associated with increased risk of human papillomavirus-related cancers, including anal cancer (HR, 2.77; 95% CI, 1.29-5.96) and female genital cancers (HR, 3.43; 95% CI, 1.44-8.19). In contrast, BCC (n = 3,669) was not associated with overall risk of later malignancy (HR, 0.98; 95% CI, 0.87-1.12), including any SCC. Our results suggest that transplant recipients with cutaneous SCC, but not BCC, have an increased risk of developing other SCC. These findings somewhat differ from those for the general population and suggest a shared etiology for cutaneous SCC and other SCC in the setting of immunosuppression. Cutaneous SCC occurrence after transplantation could serve as a marker for elevated malignancy risk. Cancer Res; 77(15); 4196-203. ©2017 AACR.
Collapse
Affiliation(s)
- Rachel D Zamoiski
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, Maryland
| | - Elizabeth Yanik
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, Maryland
| | - Todd M Gibson
- Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Elizabeth K Cahoon
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, Maryland
| | - Margaret M Madeleine
- Public Health Science, Fred Hutchinson Cancer Research Center, Seattle, Washington
| | - Charles F Lynch
- Department of Epidemiology, University of Iowa, Iowa City, Iowa
| | - Sally Gustafson
- Scientific Registry of Transplant Recipients, Minneapolis, Minnesota
| | - Marc T Goodman
- Cancer Prevention and Control Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California
| | - Melissa Skeans
- Scientific Registry of Transplant Recipients, Minneapolis, Minnesota
| | - Ajay K Israni
- Department of Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota
| | - Eric A Engels
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, Maryland
| | - Lindsay M Morton
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, Maryland.
| |
Collapse
|
24
|
Distress levels in patients with oropharyngeal vs. non-oropharyngeal squamous cell carcinomas of the head and neck over 1 year after diagnosis: a retrospective cohort study. Support Care Cancer 2017; 25:3225-3233. [PMID: 28600705 DOI: 10.1007/s00520-017-3733-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2016] [Accepted: 04/24/2017] [Indexed: 12/11/2022]
Abstract
BACKGROUND Human papillomavirus (HPV)-related cancers have been associated with different demographic profiles and disease characteristics than HPV-unrelated cancers in head and neck patients, but distress and other symptoms have not been compared. The aim of this study was to assess whether distress levels, fatigue, pain, anxiety, depression, and common psychological and practical problems differ between head and neck cancer patients with HPV-related vs. HPV-unrelated carcinomas (using oropharyngeal carcinoma (OPC) and non-OPC cancers as surrogates for HPV status). METHODS Distress, depression, anxiety, fatigue, pain, and common problems were examined in 56 OPC and 90 non-OPC patients at 4 timepoints during the first year following diagnosis. Two-level hierarchical linear modeling was used to examine effects. RESULTS The HPV-related OPC group was more likely to be younger (p = 0.05), Caucasian (p = 0.001), non-smokers (p = 0.01), earn more (p = 0.04), and present with more advanced stage (p < 0.0001). At baseline, OPC patients reported only higher pain scores (p = 0.01) than non-OPC patients. Total problems decreased more in the OPC group (p = 0.08) than the non-OPC group from baseline to 12-month follow-up. In both groups, scores on distress, depression, psychosocial problems, and practical problems decreased similarly over time. CONCLUSIONS Despite a difference in the clinico-demographic characteristics of HPV-related vs. HPV-unrelated patients, only baseline pain levels and total problems over time differed between the two groups.
Collapse
|
25
|
Chew EY, Hartman CM, Richardson PA, Zevallos JP, Sikora AG, Kramer JR, Chiao EY. Risk factors for oropharynx cancer in a cohort of HIV-infected veterans. Oral Oncol 2017; 68:60-66. [PMID: 28438295 DOI: 10.1016/j.oraloncology.2017.03.004] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2017] [Accepted: 03/11/2017] [Indexed: 11/18/2022]
Abstract
OBJECTIVE To evaluate HIV-related and other clinical risk factors associated with oropharynx cancer (OPSCC) in HIV-infected U.S. Veterans. METHODS Retrospective cohort study utilizing Veterans Affairs HIV Clinical Case Registry (CCR) data from 1985 to 2010. Outcome was incident OPSCC as indicated by 1 inpatient or 2 outpatient ICD-9 codes. Cox proportional hazard models were used to determine hazard ratios (HR) and 95% confidence intervals (CI) for each risk factor on the time to OPSCC diagnosis. RESULTS A total of 40,996 HIV-infected male veterans were included in the cohort with 97 cases of OPSCC. The age adjusted incidence rate was 23.2/100,000 [95% CI 17.8-29.2]. Age>50 (aHR=3.8, 95% CI 1.9-7.8), recent CD4<200 (aHR=3.8, 95% CI 2.0-7.3), and undetectable HIV viral loads 40-79% of the time (aHR=1.8, 95% CI 1.1-3.0) were associated with an increased risk of OPSCC. Era of HIV diagnosis, utilization of cART, nadir CD4 count, race, smoking history, and previous risk of HPV disease, including condyloma or invasive squamous cell carcinoma of the anus (SCCA) were not associated with increased risk of OPSCC. CONCLUSION Patients who were older at beginning of follow up, had lower CD4 counts around the time of OPSCC diagnosis, and moderate HIV viral control during follow-up had an increased risk of OPSCC. Other HPV-related diseases such as SCCA and condyloma did not increase the risk for OPSCC.
Collapse
Affiliation(s)
- Erin Y Chew
- One Baylor Plaza, Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX 77030, USA
| | - Christine M Hartman
- 2002 Holcombe Boulevard, Center of Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX 77030, USA
| | - Peter A Richardson
- 2002 Holcombe Boulevard, Center of Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX 77030, USA
| | - Jose P Zevallos
- 170 Manning Drive, CB# 7070 Department of Otolaryngology-Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA; 170 Rosenau Hall CB, #7400 Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA
| | - Andrew G Sikora
- One Baylor Plaza, Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, TX 77030, USA
| | - Jennifer R Kramer
- 2002 Holcombe Boulevard, Center of Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX 77030, USA
| | - Elizabeth Y Chiao
- One Baylor Plaza, Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX 77030, USA; 2002 Holcombe Boulevard, Center of Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX 77030, USA.
| |
Collapse
|
26
|
Stenmark MH, Shumway D, Guo C, Vainshtein J, Mierzwa M, Jagsi R, Griggs JJ, Banerjee M. Influence of human papillomavirus on the clinical presentation of oropharyngeal carcinoma in the United States. Laryngoscope 2017; 127:2270-2278. [PMID: 28304083 DOI: 10.1002/lary.26566] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2016] [Revised: 01/23/2017] [Accepted: 02/06/2017] [Indexed: 01/04/2023]
Abstract
OBJECTIVE Much of what is known about the significance of human papillomavirus (HPV) in oropharyngeal squamous cell carcinoma is derived from single-institution retrospective studies, post hoc analyses of tissue specimens from clinical trials, and tissue bank studies with a small sample size. The objective of this study is to investigate the impact of HPV on the frequency and clinical presentation of oropharyngeal carcinoma in a large, national sample with information from patients who underwent HPV testing. STUDY DESIGN Retrospective, cross-sectional study. METHODS We identified a comprehensive national sample of 8,359 patients with oropharyngeal carcinoma and known HPV status diagnosed between 2010 and 2011 within the National Cancer Database. Multivariable logistic regression was used to assess correlates of patient and tumor characteristics on HPV status. RESULTS Among patients with oropharyngeal carcinoma, the frequency of HPV-related squamous cell carcinoma in the United States was 65.4%. HPV-related oropharyngeal carcinoma was associated with younger age, male sex, and white race (P < 0.001). Advanced primary tumor stage was associated with HPV-negative disease (P < 0.001), whereas increasing nodal burden was associated with HPV-positive disease (P < 0.001). Despite less-advanced nodal disease, HPV-negative tumors were associated with a higher likelihood of metastasis at presentation (P < 0.001). CONCLUSION HPV now accounts for the majority of newly diagnosed oropharyngeal carcinoma in the United States and is associated with a distinct clinical profile, supporting efforts to re-evaluate the staging and treatment paradigm for HPV-associated oropharyngeal cancer. LEVEL OF EVIDENCE 4. Laryngoscope, 127:2270-2278, 2017.
Collapse
Affiliation(s)
- Matthew H Stenmark
- Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan, U.S.A
| | - Dean Shumway
- Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan, U.S.A
| | - Cui Guo
- Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, U.S.A
| | - Jeffrey Vainshtein
- Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan, U.S.A
| | - Michelle Mierzwa
- Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan, U.S.A
| | - Reshma Jagsi
- Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan, U.S.A
| | - Jennifer J Griggs
- Department of Internal Medicine, Hematology and Oncology Division, University of Michigan Medical Center, Ann Arbor, Michigan, U.S.A
| | - Mousumi Banerjee
- Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, U.S.A
| |
Collapse
|
27
|
Westrich JA, Warren CJ, Pyeon D. Evasion of host immune defenses by human papillomavirus. Virus Res 2017; 231:21-33. [PMID: 27890631 PMCID: PMC5325784 DOI: 10.1016/j.virusres.2016.11.023] [Citation(s) in RCA: 136] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2016] [Revised: 11/10/2016] [Accepted: 11/12/2016] [Indexed: 12/13/2022]
Abstract
A majority of human papillomavirus (HPV) infections are asymptomatic and self-resolving in the absence of medical interventions. Various innate and adaptive immune responses, as well as physical barriers, have been implicated in controlling early HPV infections. However, if HPV overcomes these host immune defenses and establishes persistence in basal keratinocytes, it becomes very difficult for the host to eliminate the infection. The HPV oncoproteins E5, E6, and E7 are important in regulating host immune responses. These oncoproteins dysregulate gene expression, protein-protein interactions, posttranslational modifications, and cellular trafficking of critical host immune modulators. In addition to the HPV oncoproteins, sequence variation and dinucleotide depletion in papillomavirus genomes has been suggested as an alternative strategy for evasion of host immune defenses. Since anti-HPV host immune responses are also considered to be important for antitumor immunity, immune dysregulation by HPV during virus persistence may contribute to immune suppression essential for HPV-associated cancer progression. Here, we discuss cellular pathways dysregulated by HPV that allow the virus to evade various host immune defenses.
Collapse
Affiliation(s)
- Joseph A Westrich
- Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO 80045, USA
| | - Cody J Warren
- Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO 80045, USA; Current address: BioFrontiers Institute, University of Colorado Boulder, Boulder, CO 80303, USA
| | - Dohun Pyeon
- Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO 80045, USA; Department of Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA.
| |
Collapse
|
28
|
Aldalwg MAH, Brestovac B. Human Papillomavirus Associated Cancers of the Head and Neck: An Australian Perspective. Head Neck Pathol 2017; 11:377-384. [PMID: 28176136 PMCID: PMC5550398 DOI: 10.1007/s12105-017-0780-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/16/2016] [Accepted: 01/23/2017] [Indexed: 12/15/2022]
Abstract
Human papillomavirus (HPV) associated head and neck squamous cell carcinomas (HNSCCs), have become a serious global health problem. Despite decreases in HPV-negative HNSCCs, the prevalence of HPV-positive HNSCCs has significantly increased. HPV-positive cancers are associated with superior survival outcomes when compared to HPV-negative cancers, which appears likely to be associated with differences in the molecular pathogenesis of the two diseases. While therapies are still problematic, the current HPV vaccine programs hold a promise for the primary prevention of HPV-related HNSCCs and since Australia was the first to introduce a nationwide HPV vaccine program, it is in a unique position to observe the effects of the vaccine on HNSCCs. This review discusses the epidemiological trends associated with HPV in HNSCC, with reference to the differences between HPV-positive and HPV-negative HNSCCs and the prevention potential of HPV vaccines.
Collapse
Affiliation(s)
- Marwah Abbas Hassan Aldalwg
- School of Biomedical Sciences, Curtin University, Building 308, Kent Street, Bentley, Perth, WA 6102 Australia
| | - Brian Brestovac
- School of Biomedical Sciences, Curtin University, Building 308, Kent Street, Bentley, Perth, WA 6102 Australia
| |
Collapse
|
29
|
Epithelial to mesenchymal transition and HPV infection in squamous cell oropharyngeal carcinomas: the papillophar study. Br J Cancer 2017; 116:362-369. [PMID: 28072763 PMCID: PMC5294488 DOI: 10.1038/bjc.2016.434] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2016] [Revised: 11/25/2016] [Accepted: 12/05/2016] [Indexed: 12/23/2022] Open
Abstract
Background: Human Papillomavirus (HPV) infection is recognised as aetiological factor of carcinogenesis in oropharyngeal squamous cell carcinomas (OPC). HPV-related OPC respond better to treatments and have a significantly favourable outcome. Epithelial to mesenchymal transition (EMT) implicated in tumour invasion, is a hallmark of a poor prognosis in carcinomas. Methods: We have studied the relationship of EMT markers (E-cadherin, β-catenin and vimentin) with HPV infection (DNA and E6/E7 mRNA detection), p16INK4a expression and survival outcomes in a cohort of 296 patients with OPC. Results: Among the 296 OPSSC, 26% were HPV positive, 20.3% had overt EMT (>25% of vimentin positive tumour cells). Lower E-cadherin expression was associated with a higher risk of distant metastasis in univariate (P=0.0110) and multivariate analyses (hazard ratios (HR)=6.86 (1.98; 23.84)). Vimentin expression tends towards worse metastasis-free survival (MFS; HR=2.53 (1.00; 6.41)) and was an independent prognostic factor of progression-free survival (HR=1.55 (1.03; 2.34)). Conclusions: There was a non significant association of EMT with HPV status. This may be explained by a mixed subpopulation of patients HPV positive with associated risk factors (HPV, tobacco and alcohol). Thus, the detection of EMT in OPC represents another reliable approach in the prognosis and the management of OPC whatever their HPV status.
Collapse
|
30
|
Fang CY, Heckman CJ. Informational and Support Needs of Patients with Head and Neck Cancer: Current Status and Emerging Issues. CANCERS OF THE HEAD & NECK 2016; 1. [PMID: 28670482 PMCID: PMC5488795 DOI: 10.1186/s41199-016-0017-6] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The objective of this article is to review and summarize the extant literature on head and neck cancer (HNC) patients’ informational needs and to characterize emerging issues in this patient population in order to define priorities for future research. HNC patients may undergo challenging treatment regimens and experience treatment-related alterations in primary daily functions such as speech and eating. These changes often persist following treatment and may lead to significant deficits in quality of life and interpersonal relations. Despite empirical evidence demonstrating that receipt of adequate information and support is predictive of improved outcomes post-treatment, relatively limited attention has been paid to the informational and support needs of HNC patients. This review focuses primarily on three topic domains: (1) managing treatment-related side effects; (2) addressing alcohol and tobacco dependence; and (3) informational needs in the areas of human papillomavirus (HPV) and clinical trials. While there is increasing awareness of the rehabilitation and survivorship needs in this patient population, patients note that the impact of treatment on social activities and interactions is under-discussed and of key concern. In addition, there is a significant gap in addressing communication and informational needs of caregivers and family members who are integral for promoting healthy behaviors and self-care post-treatment. Greater integration of programs that address tobacco or alcohol dependency within a comprehensive treatment and support plan may increase patient motivation to seek help and enhance patient success in maintaining long-term abstinence. Finally, emerging patient-provider communication needs, particularly in the context of decision making about clinical trials or surrounding an HPV-related diagnosis, have been noted among both patients and healthcare providers. Future research on the development of novel programs that offer feasible and acceptable methods for addressing unmet informational and support needs is warranted and may yield benefit for improving patient-reported outcomes.
Collapse
Affiliation(s)
- Carolyn Y Fang
- Fox Chase Cancer Center, 333 Cottman Ave., Philadelphia, PA
| | | |
Collapse
|
31
|
Auluck A, Walker BB, Hislop G, Lear SA, Schuurman N, Rosin M. Socio-economic deprivation: a significant determinant affecting stage of oral cancer diagnosis and survival. BMC Cancer 2016; 16:569. [PMID: 27480165 PMCID: PMC4970228 DOI: 10.1186/s12885-016-2579-4] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2016] [Accepted: 07/18/2016] [Indexed: 01/16/2023] Open
Abstract
Background Many factors contribute to socioeconomic status (SES), yet in most survival studies only income is used as a measure for determining SES. We used a complex, composite, census-based metric for socioeconomic deprivation to better distinguish individuals with lower SES and assess its impact on survival and staging trends of oral cancers. Methods Oropharyngeal (OPC) and oral cavity cancer (OCC) cases were identified from the British Columbia cancer registry between 1981–2009 and placed into affluent and deprived neighborhoods using postal codes linked to VANDIX (a composite SES index based on 7 census variables encompassing income, housing, family structure, education, and employment). Stage and cancer-specific survival rates were examined by sex, SES, and time period. Results Approximately 50 % of OPC and OCC cases of both sexes resided in SES deprived neighborhoods. Numbers of cases have increased in recent years for all but OCC in men. The deprivation gap in survival between affluent and deprived neighborhoods widened in recent years for OPC and OCC in men, while decreasing for OPC and increasing slightly for OCC in women. Greater proportions of OCC cases were diagnosed at later stage disease for both sexes residing in deprived neighborhoods, a trend not seen for OPC. Conclusion SES remains a significant independent determinant of survival for both OPC and OCC when using a composite metric for SES. OPC survival rates among men have improved, albeit at slower rates in deprived communities. OCC screening programs need to be targeted towards SES-deprived neighborhoods where greater proportions of cases were diagnosed at a later stage and survival rates have significantly worsened in both sexes.
Collapse
Affiliation(s)
- Ajit Auluck
- Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, Canada. .,Cancer Control Research Department, BC Cancer Agency, Vancouver, Canada. .,BC Oral Cancer Prevention Program, BC Cancer Agency Research Centre, 675 W. 10th Ave, 3rd Floor, Room 119, Vancouver, B.C, V5Z1L3, Canada.
| | | | - Greg Hislop
- Cancer Control Research Department, BC Cancer Agency, Vancouver, Canada
| | - Scott A Lear
- Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, Canada.,Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada.,Division of Cardiology, Providence Health Care, Vancouver, Canada
| | - Nadine Schuurman
- Department of Geography, Simon Fraser University, Burnaby, BC, Canada
| | - Miriam Rosin
- Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, Canada.,Cancer Control Research Department, BC Cancer Agency, Vancouver, Canada
| |
Collapse
|
32
|
Lam JO, Lim WY, Chow KY, D’Souza G. Incidence, Trends and Ethnic Differences of Oropharyngeal, Anal and Cervical Cancers: Singapore, 1968-2012. PLoS One 2015; 10:e0146185. [PMID: 26720001 PMCID: PMC4705110 DOI: 10.1371/journal.pone.0146185] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2015] [Accepted: 12/14/2015] [Indexed: 02/07/2023] Open
Abstract
In recent decades, several Western countries have reported an increase in oropharyngeal and anal cancers caused by human papillomavirus (HPV). Trends in HPV-associated cancers in Asia have not been as well described. We describe the epidemiology of potentially HPV-related cancers reported to the Singapore Cancer Registry from 1968-2012. Analysis included 998 oropharyngeal squamous cell carcinoma (OPSCC), 183 anal squamous cell carcinoma (ASCC) and 8,019 invasive cervical cancer (ICC) cases. Additionally, 368 anal non-squamous cell carcinoma (ANSCC) and 2,018 non-oropharyngeal head and neck carcinoma (non-OP HNC) cases were included as comparators. Age-standardized incidence rates (ASR) were determined by gender and ethnicity (Chinese, Malay and Indian). Joinpoint regression was used to evaluate annual percentage change (APC) in incidence. OPSCC incidence increased in both genders (men 1993-2012, APC = 1.9%, p<0.001; women 1968-2012, APC = 2.0%, p = 0.01) and was 5 times higher in men than women. In contrast, non-OP HNC incidence declined between 1968-2012 among men (APC = -1.6%, p<0.001) and women (APC = -0.4%, p = 0.06). ASCC and ANSCC were rare (ASR = 0.2 and 0.7 per 100,000 person-years, respectively) and did not change significantly over time except for increasing ANSCCs in men (APC = 2.8%, p<0.001). ICC was the most common HPV-associated cancer (ASR = 19.9 per 100,000 person-years) but declined significantly between 1968-2012 (APC = -2.4%). Incidence of each cancer varied across ethnicities. Similar to trends in Western countries, OPSCC incidence increased in recent years, while non-OP HNC decreased. ICC remains the most common HPV-related cancer in Singapore, but Pap screening programs have led to consistently decreasing incidence.
Collapse
Affiliation(s)
- Jennifer O. Lam
- Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States of America
| | - Wei-Yen Lim
- Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore
| | - Khuan-Yew Chow
- National Registry of Diseases Office, Singapore, Singapore
| | - Gypsyamber D’Souza
- Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States of America
- * E-mail:
| |
Collapse
|
33
|
Silverberg MJ, Lau B, Achenbach CJ, Jing Y, Althoff KN, D'Souza G, Engels EA, Hessol NA, Brooks JT, Burchell AN, Gill MJ, Goedert JJ, Hogg R, Horberg MA, Kirk GD, Kitahata MM, Korthuis PT, Mathews WC, Mayor A, Modur SP, Napravnik S, Novak RM, Patel P, Rachlis AR, Sterling TR, Willig JH, Justice AC, Moore RD, Dubrow R. Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med 2015; 163:507-18. [PMID: 26436616 PMCID: PMC4711936 DOI: 10.7326/m14-2768] [Citation(s) in RCA: 235] [Impact Index Per Article: 23.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND Cancer is increasingly common among persons with HIV. OBJECTIVE To examine calendar trends in cumulative cancer incidence and hazard rate by HIV status. DESIGN Cohort study. SETTING North American AIDS Cohort Collaboration on Research and Design during 1996 to 2009. PARTICIPANTS 86 620 persons with HIV and 196 987 uninfected adults. MEASUREMENTS Cancer type-specific cumulative incidence by age 75 years and calendar trends in cumulative incidence and hazard rates, each by HIV status. RESULTS Cumulative incidences of cancer by age 75 years for persons with and without HIV, respectively, were as follows: Kaposi sarcoma, 4.4% and 0.01%; non-Hodgkin lymphoma, 4.5% and 0.7%; lung cancer, 3.4% and 2.8%; anal cancer, 1.5% and 0.05%; colorectal cancer, 1.0% and 1.5%; liver cancer, 1.1% and 0.4%; Hodgkin lymphoma, 0.9% and 0.09%; melanoma, 0.5% and 0.6%; and oral cavity/pharyngeal cancer, 0.8% and 0.8%. Among persons with HIV, calendar trends in cumulative incidence and hazard rate decreased for Kaposi sarcoma and non-Hodgkin lymphoma. For anal, colorectal, and liver cancer, increasing cumulative incidence, but not hazard rate trends, were due to the decreasing mortality rate trend (-9% per year), allowing greater opportunity to be diagnosed. Despite decreasing hazard rate trends for lung cancer, Hodgkin lymphoma, and melanoma, cumulative incidence trends were not seen because of the compensating effect of the declining mortality rate. LIMITATION Secular trends in screening, smoking, and viral co-infections were not evaluated. CONCLUSION Cumulative cancer incidence by age 75 years, approximating lifetime risk in persons with HIV, may have clinical utility in this population. The high cumulative incidences by age 75 years for Kaposi sarcoma, non-Hodgkin lymphoma, and lung cancer support early and sustained antiretroviral therapy and smoking cessation.
Collapse
Affiliation(s)
- Michael J. Silverberg
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - Bryan Lau
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - Chad J. Achenbach
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - Yuezhou Jing
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - Keri N. Althoff
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - Gypsyamber D'Souza
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - Eric A. Engels
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - Nancy A. Hessol
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - John T. Brooks
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - Ann N. Burchell
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - M. John Gill
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - James J. Goedert
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - Robert Hogg
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - Michael A. Horberg
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - Gregory D. Kirk
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - Mari M. Kitahata
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - Philip T. Korthuis
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - William C. Mathews
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - Angel Mayor
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - Sharada P. Modur
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - Sonia Napravnik
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - Richard M. Novak
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - Pragna Patel
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - Anita R. Rachlis
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - Timothy R. Sterling
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - James H. Willig
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - Amy C. Justice
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - Richard D. Moore
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | - Robert Dubrow
- From Kaiser Permanente Northern California, Oakland, California; Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Northwestern University Feinberg School of Medicine, Center for Global Health, Lurie Cancer Center, and College of Medicine, University of Illinois at Chicago, Chicago, Illinois; National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- University of California, San Francisco, San Francisco, California; Centers for Disease Control and Prevention, Atlanta, Georgia; Ontario HIV Treatment Network, Dalla Lana School of Public Health, and Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; University of Calgary, Calgary, Alberta, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada; Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, Maryland; University of Washington, Seattle, Washington; Oregon Health and Sciences University, Portland, Oregon; University of California, San Diego, San Diego, California; Retrovirus Research Center, Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico
- School of Medicine, University of North Carolina, Chapel Hill, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Alabama, Birmingham, Alabama; Veterans Affairs Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, Connecticut
| | | |
Collapse
|
34
|
Ye A, Bradley KL, Kader H, Wu J, Hay JH. Patterns of Relapse in Squamous Cell Carcinoma of the Tonsil - Unilateral vs. Bilateral Radiation in the HPV-Era. Cureus 2015; 7:e322. [PMID: 26487998 PMCID: PMC4601887 DOI: 10.7759/cureus.322] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
OBJECTIVES In the pre-human papillomavirus (HPV) era, unilateral radiation therapy (URT) for tonsil cancer was associated with low contralateral failure rates and had less toxicity than bilateral radiation therapy (BRT). This study explores the validity of URT in HPV-positive tonsil cancers. METHODS Tonsil squamous cell carcinomas (SCC) treated (typically with 70 Gy radiation and Cisplatin-based chemotherapy) between 2001 and 2007 were reviewed. Retrospective p16 immunohistochemistry staining was undertaken. Baseline, treatment, and response data were collected. RESULTS Of 182 patients, 78% were p16-positive, were younger (predominantly male), mostly former or non-smokers, and had a more advanced nodal stage. With a median follow-up of 68 months, contralateral recurrence (CLR) rates were low (3.5% p16-positive versus 2.5% p16-negative, p=0.63). Overall survival (OS) was 74% for p16-positive versus 54% for p16-negative subjects (p=0.01), but all other outcomes were similar. Analysis amongst only p16-positive subjects revealed URT was delivered to 37%, with CLR rates of 7.5% versus 1.1% for those treated with BRT, p=0.05. Of the four p16-positive subjects treated with URT who developed contralateral recurrences, three were managed with neck dissection (two disease-free and one died of lung metastases) and one received palliative radiation to the neck and distant metastatic site. All disease control and survival outcomes were similar between those treated with URT versus BRT. CONCLUSION While CLRs remain rare overall, there appears to be a slightly increased rate among HPV-positive subjects treated with URT. However, overall outcomes do not appear to be impacted, suggesting that URT remains a reasonable approach in HPV-positive subjects.
Collapse
Affiliation(s)
- Allison Ye
- Department of Radiation Oncology, British Columbia Cancer Agency - Vancouver Cancer Centre
| | | | - Hosam Kader
- Department of Radiation Oncology, British Columbia Cancer Agency - Vancouver Cancer Centre
| | - John Wu
- Department of Radiation Oncology, British Columbia Cancer Agency - Vancouver Cancer Centre
| | - John H Hay
- Department of Radiation Oncology, British Columbia Cancer Agency - Vancouver Cancer Centre
| |
Collapse
|
35
|
Walker BB, Schuurman N, Auluck A, Lear SA, Rosin M. Suburbanisation of oral cavity cancers: evidence from a geographically-explicit observational study of incidence trends in British Columbia, Canada, 1981-2010. BMC Public Health 2015; 15:758. [PMID: 26253077 PMCID: PMC4528809 DOI: 10.1186/s12889-015-2111-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2015] [Accepted: 07/29/2015] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND Recent studies have demonstrated an elevated risk of oral cavity cancers (OCC) among socioeconomically deprived populations, whose increasing presence in suburban neighbourhoods poses unique challenges for equitable health service delivery. The majority of studies to date have utilised aspatial methods to identify OCC. In this study, we use high-resolution geographical analyses to identify spatio-temporal trends in OCC incidence, emphasising the value of geospatial methods for public health research. METHODS Using province-wide population incidence data from the British Columbia Cancer Registry (1981-2009, N = 5473), we classify OCC cases by census-derived neighbourhood types to differentiate between urban, suburban, and rural residents at the time of diagnosis. We map geographical concentrations by decade and contrast trends in age-adjusted incidence rates, comparing the results to an index of socioeconomic deprivation. RESULTS Suburban cases were found to comprise a growing proportion of OCC incidence. In effect, OCC concentrations have dispersed from dense urban cores to suburban neighbourhoods in recent decades. Significantly higher age-adjusted oral cancer incidence rates are observed in suburban neighbourhoods from 2006 to 2009, accompanied by rising socioeconomic deprivation in those areas. New suburban concentrations of incidence were found in neighbourhoods with a high proportion of persons aged 65+ and/or born in India, China, or Taiwan. CONCLUSIONS While the aging of suburban populations provides some explanation of these trends, we highlight the role of the suburbanisation of socioeconomically deprived and Asia-born populations, known to have higher rates of risk behaviours such as tobacco, alcohol, and betel/areca consumption. Specifically, betel/areca consumption among Asia-born populations is suspected to be a primary driver of the observed geographical shift in incidence from urban cores to suburban neighbourhoods. We suggest that such geographically-informed findings are complementary to potential and existing place-specific cancer control policy and targeting prevention efforts for high-risk sub-populations, and call for the supplementation of epidemiological studies with high-resolution mapping and geospatial analysis.
Collapse
Affiliation(s)
- Blake Byron Walker
- Department of Geography, Simon Fraser University, 8888 University Drive, Burnaby, BC, V5A 1S6, Canada.
| | - Nadine Schuurman
- Department of Geography, Simon Fraser University, 8888 University Drive, Burnaby, BC, V5A 1S6, Canada
| | - Ajit Auluck
- British Columbia Cancer Agency, Vancouver, BC, Canada
- Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada
| | - Scott A Lear
- Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada
- Division of Cardiology, Providence Health Care, Vancouver, BC, Canada
| | - Miriam Rosin
- British Columbia Cancer Agency, Vancouver, BC, Canada
- Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
| |
Collapse
|
36
|
Beachler DC, Abraham AG, Silverberg MJ, Jing Y, Fakhry C, Gill MJ, Dubrow R, Kitahata MM, Klein MB, Burchell AN, Korthuis PT, Moore RD, D'Souza G. Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individuals. Oral Oncol 2014; 50:1169-76. [PMID: 25301563 PMCID: PMC4253676 DOI: 10.1016/j.oraloncology.2014.09.011] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2014] [Revised: 09/14/2014] [Accepted: 09/18/2014] [Indexed: 12/31/2022]
Abstract
OBJECTIVES To examine the risk and trends of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma (HNSCC) in HIV-infected individuals and assess whether immunosuppression (measured through CD4 cell count) and other risk factors impact HNSCC risk. MATERIALS AND METHODS Incident HNSCCs at HPV-related and HPV-unrelated anatomic sites were detected in HIV-infected participants from pooled data from 17 prospective studies in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) between 1996 and 2009. HNSCC cases were validated using chart review or cancer registry matching. Risk factors for incident HPV-related and HPV-unrelated HNSCC were explored using mixed effects Poisson regression in a full prospective analysis, and the effect of CD4 prior to cancer diagnosis was examined in a nested case control analysis. RESULTS 66 HPV-related and 182 HPV-unrelated incident HNSCCs were detected among 82,375 HIV-infected participants. Standardized incidence ratios (SIRs) for both HPV-related (SIR=3.2, 95%CI=2.5-3.4) and HPV-unrelated (SIR=3.0, 95%CI=2.5-4.1) HNSCC were significantly elevated in HIV-infected individuals compared with the US general population. Between 1996 and 2009, the age-standardized HPV-related HNSCC incidence increased non-significantly from 6.8 to 11.4per 100,000 person-years (p-trend=0.31) while the age-standardized incidence of HPV-unrelated HNSCC decreased non-significantly from 41.9 to 29.3 per 100,000 person-years (p-trend=0.16). Lower CD4 cell count prior to cancer diagnosis was significantly associated with increased HPV-related and HPV-unrelated HNSCC risk. CONCLUSION The standardized incidence of HPV-related and HPV-unrelated HNSCC are both elevated in HIV-infected individuals. Immunosuppression may have a role in the development of both HPV-related and HPV-unrelated HNSCC.
Collapse
Affiliation(s)
- Daniel C Beachler
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe St., Baltimore, MD, USA.
| | - Alison G Abraham
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe St., Baltimore, MD, USA.
| | - Michael J Silverberg
- Division of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, USA.
| | - Yuezhou Jing
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe St., Baltimore, MD, USA.
| | - Carole Fakhry
- Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins Hospital, 601 N. Caroline St., Baltimore, MD, USA.
| | - M John Gill
- Department of Medicine, University of Calgary, 3330 Hospital Dr. NW., Calgary, Canada.
| | - Robert Dubrow
- Cancer Prevention and Control Program, Yale School of Public Health and Yale School of Medicine, P.O. Box 208034, 60 College Street, New Haven, CT, USA.
| | | | - Marina B Klein
- Division of Medicine, McGill University, 3655 Sir William Osler, Montreal, Quebec, Canada.
| | - Ann N Burchell
- Division of Oncology, Ontario HIV Treatment Network, 1300 Yong St. Suite 600, Toronto, Ontario, Canada.
| | - P Todd Korthuis
- Department of Public Health/Preventive Medicine, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Rd., Portland, OR, USA.
| | - Richard D Moore
- Department of Medicine, Johns Hopkins University, 1830 E. Monument St., Baltimore, MD, USA.
| | - Gypsyamber D'Souza
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe St., Baltimore, MD, USA.
| |
Collapse
|
37
|
Friedman JM, Stavas MJ, Cmelak AJ. Clinical and scientific impact of human papillomavirus on head and neck cancer. World J Clin Oncol 2014; 5:781-91. [PMID: 25302178 PMCID: PMC4129541 DOI: 10.5306/wjco.v5.i4.781] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/25/2013] [Revised: 04/21/2014] [Accepted: 05/15/2014] [Indexed: 02/06/2023] Open
Abstract
Head and neck cancer (HNC) arises from the skull base to the clavicles and is the fifth most common cancer in the world by incidence. Historically, in the developed world HNC was associated with tobacco use and alcohol consumption, and the combination of the two produced a synergistic increase in risk. However, beginning in 1983, investigators have found a significant and growing proportion of HNC patients with human papillomavirus-positive (HPV) tumors who neither drank nor used tobacco. Since that time, there has been increased interest in the molecular biology of HPV-positive HNC. Multiple studies now show that HPV has shifted the epidemiological landscape and prognosis of head and neck squamous cell carcinoma (HNSCC). These studies provide strong evidence for improved survival outcomes in patients with HPV-positive HNSCC compared to those with HPV-negative HNSCC. In many reports, HPV status is the strongest predictor of locoregional control, disease specific survival and overall survival. In response to these findings, there has been significant interest in the best management of HPV-positive disease. Discussions within major cooperative groups consider new trials designed to maintain the current strong survival outcomes while reducing the long-term treatment-related toxicities. This review will highlight the epidemiological, clinical and molecular discoveries surrounding HPV-related HNSCC over the recent decades and we conclude by suggesting how these findings may guide future treatment approaches.
Collapse
|
38
|
Shack L, Lau HY, Huang L, Doll C, Hao D. Trends in the incidence of human papillomavirus-related noncervical and cervical cancers in Alberta, Canada: a population-based study. CMAJ Open 2014; 2:E127-32. [PMID: 25114894 PMCID: PMC4117359 DOI: 10.9778/cmajo.20140005] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
INTRODUCTION Recent epidemiologic studies have suggested that the incidence of noncervical cancers associated with human papillomavirus (HPV) is increasing. We assessed temporal, age-specific and sex-specific changes in the incidence of HPV-associated cancers in a population-based study. METHODS We used the Alberta Cancer Registry, a registry of all cancers diagnosed in the province of Alberta, Canada, to identify patients with cancers of the oropharynx, cervix, vulva, vagina, anus and penis (cancers associated with HPV) between Jan. 1, 1975, and Dec. 31, 2009. We estimated the age-standardized incidence of each cancer by sex- and age-specific group and assessed the annual percentage change using joinpoint regression. RESULTS The age-standardized incidence of oropharyngeal cancers increased for each 5-year interval of the study period among men (annual percentage change 3.4, p < 0.001) and women (annual percentage change 1.5, p = 0.009). For anal cancers, the age-standardized rates increased among women (annual percentage change 2.2, p < 0.001) and men (annual percentage change 1.8, p = 0.008). The age-standardized incidence of cervical cancer increased with age, reaching an annual percentage change of -3.5 among women aged 75-84 years (p = 0.04). The rates of other HPV-associated cancers (vulvar, vaginal and penile) showed little change. INTERPRETATION Our findings showed increases in the incidence of the HPV-associated cancers of the oropharynx and anus among men and women, and increases in cervical cancer among younger women. The incidence of HPV-related cancers in younger age groups should continue to be monitored. Programs to prevent HPV infection, such as vaccination, should be considered for males as well as females.
Collapse
Affiliation(s)
- Lorraine Shack
- Surveillance and Reporting, Cancer Control Alberta, Alberta Health Services, Calgary, Alta
- Department of Oncology, Faculty of Medicine, University of Calgary, Calgary, Alta
- Community Health Sciences, Faculty of Medicine, University of Calgary, Calgary Alta
| | - Harold Y. Lau
- Department of Oncology, Faculty of Medicine, University of Calgary, Calgary, Alta
- Division of Radiation Oncology, Department of Oncology, Tom Baker Cancer Centre, Alberta Health Services, Calgary, Alta
| | - Longlong Huang
- Department of Mathematics and Statistics, University of Calgary, Calgary, Alta
| | - Corinne Doll
- Department of Oncology, Faculty of Medicine, University of Calgary, Calgary, Alta
- Division of Radiation Oncology, Department of Oncology, Tom Baker Cancer Centre, Alberta Health Services, Calgary, Alta
| | - Desirée Hao
- Department of Oncology, Faculty of Medicine, University of Calgary, Calgary, Alta
- Division of Medical Oncology, Department of Oncology, Tom Baker Cancer Centre, Alberta Health Services, Calgary, Alta
| |
Collapse
|
39
|
Woods RSR, O’Regan EM, Kennedy S, Martin C, O’Leary JJ, Timon C. Role of human papillomavirus in oropharyngeal squamous cell carcinoma: A review. World J Clin Cases 2014; 2:172-193. [PMID: 24945004 PMCID: PMC4061306 DOI: 10.12998/wjcc.v2.i6.172] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/02/2014] [Revised: 04/21/2014] [Accepted: 05/19/2014] [Indexed: 02/05/2023] Open
Abstract
Human papillomavirus (HPV) has been implicated in the pathogenesis of a subset of oropharyngeal squamous cell carcinoma. As a result, traditional paradigms in relation to the management of head and neck squamous cell carcinoma have been changing. Research into HPV-related oropharyngeal squamous cell carcinoma is rapidly expanding, however many molecular pathological and clinical aspects of the role of HPV remain uncertain and are the subject of ongoing investigation. A detailed search of the literature pertaining to HPV-related oropharyngeal squamous cell carcinoma was performed and information on the topic was gathered. In this article, we present an extensive review of the current literature on the role of HPV in oropharyngeal squamous cell carcinoma, particularly in relation to epidemiology, risk factors, carcinogenesis, biomarkers and clinical implications. HPV has been established as a causative agent in oropharyngeal squamous cell carcinoma and biologically active HPV can act as a prognosticator with better overall survival than HPV-negative tumours. A distinct group of younger patients with limited tobacco and alcohol exposure have emerged as characteristic of this HPV-related subset of squamous cell carcinoma of the head and neck. However, the exact molecular mechanisms of carcinogenesis are not completely understood and further studies are needed to assist development of optimal prevention and treatment modalities.
Collapse
|
40
|
Baumeister P, Reiter M, Welz C, Becker S, Betz C, Harréus U. Surgically treated oropharyngeal cancer: risk factors and tumor characteristics. J Cancer Res Clin Oncol 2014; 140:1011-9. [PMID: 24615330 DOI: 10.1007/s00432-014-1631-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2014] [Accepted: 02/27/2014] [Indexed: 12/21/2022]
Abstract
PURPOSE To assess risk factors of patients with oropharyngeal squamous cell carcinoma in the Munich area of Southern Germany in relation to human papillomavirus (HPV) association of the tumors. To demonstrate differences in tumor characteristics and their impact on adjuvant treatment. METHODS Between November 2010 and July 2013, patients were prospectively interviewed for risk factors before they underwent surgical resection of their tumors. HPV association was evaluated by p16 immunohistochemistry; tumor characteristics and type of adjuvant treatment were recorded. Follow-up data were collected after a median follow-up of 12.1 month. RESULTS In contrast to many recent studies, we could not detect any difference in overall age and age at sexual debut between p16-positive and p16-negative patients. P16-negative patients are characterized by a more intensive tobacco and alcohol use, a more abusive way of consumption, less nonoral and less oral sex partners. P16-positive patients had a significantly higher risk of lymph node metastases, but nevertheless a significant lower risk to recur or to die. No difference in the incidence of synchronous second primary tumors was seen. P16-positive patients generally received a more aggressive adjuvant treatment because of more frequently involved lymph nodes. CONCLUSION Lifestyle risk factors such as smoking, drinking, and sexual habits were independent from age, but showed marked differences between the p16-positive and p16-negative group. Since p16-positive patients were treated more aggressively, it is not possible to distinguish whether the better outcome of HPV-positive patients is a result of less aggressive cancers or more aggressive treatment. With regard to the ongoing debate about treatment deintensification, we should keep in mind that the survival of HPV-positive cancer patients is not 100 %.
Collapse
Affiliation(s)
- Philipp Baumeister
- Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig-Maximilians-University, Munich, Germany,
| | | | | | | | | | | |
Collapse
|
41
|
Auluck A, Walker BB, Hislop G, Lear SA, Schuurman N, Rosin M. Population-based incidence trends of oropharyngeal and oral cavity cancers by sex among the poorest and underprivileged populations. BMC Cancer 2014; 14:316. [PMID: 24886308 PMCID: PMC4022437 DOI: 10.1186/1471-2407-14-316] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2014] [Accepted: 04/22/2014] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Oral cancer is an important health issue, with changing incidence in many countries. Oropharyngeal cancer (OPC, in tonsil and oropharygeal areas) is increasing, while oral cavity cancer (OCC, other sites in the mouth) is decreasing. There is the need to identify high risk groups and communities for further study and intervention. The objective of this study was to determine how the incidence of OPC and OCC varied by neighbourhood socioeconomic status (SES) in British Columbia (BC), including the magnitude of any inequalities and temporal trends. METHODS ICDO-3 codes were used to identify OPC and OCC cases in the BC Cancer Registry from 1981-2010. Cases were categorized by postal codes into SES quintiles (q1-q5) using VANDIX, which is a census-based, multivariate weighted index based on neighbourhood average household income, housing tenure, educational attainment, employment and family structure. Age-standardized incidence rates were determined for OPC and OCC by sex and SES quintiles and temporal trends were then examined. RESULTS Incidence rates are increasing in both men and women for OPC, and decreasing in men and increasing in women for OCC. This change is not linear or proportionate between different SES quintiles, for there is a sharp and dramatic increase in incidence according to the deprivation status of the neighbourhood. The highest incidence rates in men for both OPC and OCC were observed in the most deprived SES quintile (q5), at 1.7 times and 2.2 times higher, respectively, than men in the least deprived quintile (q1). For OPC, the age-adjusted incidence rates significantly increased in all SES quintiles with the highest increase observed in the most deprived quintile (q5). Likewise, the highest incidence rates for both OPC and OCC in women were observed in the most deprived SES quintile (q5), at 2.1 times and 1.8 times higher, respectively, than women in the least deprived quintile (q1). CONCLUSION We report on SES disparities in oral cancer, emphasizing the need for community-based interventions that address access to medical care and the distribution of educational and health promotion resources among the most SES deprived communities in British Columbia.
Collapse
Affiliation(s)
- Ajit Auluck
- Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, Canada
- Cancer Control Research Department, BC Cancer Agency, Research Centre, 675 W. 10th Ave, 3rd Floor, Room 119, V5Z1L3 Vancouver, B.C, Canada
| | | | - Greg Hislop
- Cancer Control Research Department, BC Cancer Agency, Research Centre, 675 W. 10th Ave, 3rd Floor, Room 119, V5Z1L3 Vancouver, B.C, Canada
| | - Scott A Lear
- Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, Canada
- Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
- Division of Cardiology, Providence Health Care, St. Paul’s Hospital, Vancouver, Canada
| | - Nadine Schuurman
- Department of Geography, Simon Fraser University, Burnaby, BC, Canada
| | - Miriam Rosin
- Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, Canada
- Cancer Control Research Department, BC Cancer Agency, Research Centre, 675 W. 10th Ave, 3rd Floor, Room 119, V5Z1L3 Vancouver, B.C, Canada
| |
Collapse
|
42
|
Colon-López V, Quiñones-Avila V, Del Toro-Mejías LM, Reyes K, Rivera ME, Nieves K, Sánchez-Vazquez MM, Martínez-Ferrer M, Ortiz AP. Oral HPV infection in a clinic-based sample of Hispanic men. BMC Oral Health 2014; 14:7. [PMID: 24460642 PMCID: PMC3906756 DOI: 10.1186/1472-6831-14-7] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2013] [Accepted: 01/09/2014] [Indexed: 11/24/2022] Open
Abstract
BACKGROUND Human papillomavirus (HPV) is associated to the pathogenesis of various cancers, such as oropharyngeal squamous cell carcinoma, which has a high incidence in Puerto Rican men. Despite the burden of oral cancer in Puerto Rico, little is known about the epidemiology of oral HPV infection, particularly in high-risk men. Therefore, this study is aimed at determining the prevalence of oral HPV infection, the genotype distribution and correlates associated with oral HPV infection in men of at least 16 years of age attending a sexually transmitted infection (STI) clinic in Puerto Rico. METHODS A cross-sectional study consisting of 205 men was conducted. Participants provided a 30-second oral rinse and gargle with mouthwash. Following DNA extraction, HPV genotyping was performed in all samples using Innogenetics Line Price Assay (INNO-LiPA). A questionnaire was administered, which included a demographic, behavioral and a clinical assessment. Descriptive statistics and bivariate analysis were used to characterize the study sample. Variables that achieved statistical significance in the bivariate analysis (p < 0.05) were assessed in multivariate logistic regression models. RESULTS The mean age of the study sample was 38.5 ± 14.2 years. Oral HPV prevalence among men was 20.0% (95.0%CI = 14.8%-26.1%) and of HPV type 16 was 2.4% (95.0%CI = 0.8%-5.6%). Oral HPV prevalence significantly increased over increasing age categories (p-trend = 0.001). Multivariate analysis showed that oral HPV was independently associated with number of sexual partners (adjusted OR = 1.02; 95%CI = 1.01-1.03) and lifetime use of cigarettes (adjusted OR = 3.00; 95%CI = 0.98-9.16). CONCLUSIONS Oral HPV among the sampled men in the STI clinic was high, regardless of the HIV status or sexual behavior. Interventions in STI clinics should include screening for HPV in the oral cavity for the early detection and reduction of long-term consequences of oral HPV infection, such as oropharyngeal cancer.
Collapse
Affiliation(s)
- Vivian Colon-López
- Cancer Control and Population Sciences Program, University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico
- Department of Health Services Administration, Graduate School of Public Health, University of Puerto Rico, San Juan, Puerto Rico
| | - Valerie Quiñones-Avila
- Department of Health Services Administration, Graduate School of Public Health, University of Puerto Rico, San Juan, Puerto Rico
| | - Lizbeth M Del Toro-Mejías
- UPR/MDACC: Partnership for Excellence in Cancer Research Program, School of Medicine, University of Puerto Rico, San Juan, Puerto Rico
| | - Keysha Reyes
- Universidad Autónoma de Guadalajara, Zapopan, Mexico
| | - Manuel E Rivera
- Río Piedras Campus, University of Puerto Rico, San Juan, Puerto Rico
| | - Kathleen Nieves
- Río Piedras Campus, University of Puerto Rico, San Juan, Puerto Rico
| | | | - Magaly Martínez-Ferrer
- University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico
- Department of Pharmaceutical Sciences, School of Pharmacy, University of Puerto Rico, San Juan, Puerto Rico
| | - Ana P Ortiz
- Cancer Control and Population Sciences Program, University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico
- Department of Biostatistics and Epidemiology, Graduate School of Public Health, University of Puerto Rico, San Juan, Puerto Rico
| |
Collapse
|
43
|
The relationship between survival and socio-economic status for head and neck cancer in Canada. J Otolaryngol Head Neck Surg 2014; 43:2. [PMID: 24422754 PMCID: PMC3896831 DOI: 10.1186/1916-0216-43-2] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2013] [Accepted: 12/16/2013] [Indexed: 11/17/2022] Open
Abstract
Background Human papilloma virus (HPV) is emerging as the primary cause for some head and neck cancers. The objective of this study was to investigate the association between head and neck cancer (HNC) survival and socioeconomic status (SES) in Canada, and to investigate changes in the relationship between HNC survival and SES from 1992 to 2005. Methods Cases were drawn from the Canadian Cancer Registry (1992–2005), and were categorized into three subsites: oropharynx, oral cavity, and “other” (hypopharynx, larynx, and nasopharynx). Demographic and socioeconomic information were extracted from the Canadian Census of Population data for the study period, which included three census years: 1991, 1996 and 2001. We linked cases to income quintiles (InQs) according to patients’ postal codes. Results Overall survival, without controlling for smoking, for oropharyngeal cancer increased dramatically from 1992–2005 in Canada. This increase in survival for oropharynx cancer was eliminated by the introduction of controls for smoking. Survival for all head and neck cancer subsites was strongly correlated with SES, as measured by income quintile, with lower InQ’s having lower survival than higher. Lastly, the magnitude of the difference in survival between the highest and lowest income quintiles increased significantly over the time period studied for oropharynx cancer, but did not statistically significantly change for oral cavity cancer or other head and neck cancers. Conclusions These data confirm a significant impact of socioeconomic deprivation on overall survival for head and neck cancers in Canada, and may provide indirect evidence that HPV-positive head and neck cancers are more common in higher socioeconomic groups.
Collapse
|
44
|
Teng WQ, Chen XP, Xue XC, Zhang Y, Tan XJ, Sun G, Wang Y, Wang L. Distribution of 37 human papillomavirus types in parotid gland tumor tissues. Oncol Lett 2013; 7:834-838. [PMID: 24527091 PMCID: PMC3919866 DOI: 10.3892/ol.2013.1770] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2013] [Accepted: 11/04/2013] [Indexed: 01/02/2023] Open
Abstract
Human papillomavirus (HPV) infection has been shown to be associated with human tumorigenesis. The aim of the present study was to demonstrate the association between HPV infection and parotid gland tumors. Paraffin-embedded tissue sections from 59 cases of parotid gland tumors and 20 normal oral mucosa were subjected to DNA extraction and flow-through hybridization and gene chip technology to detect infection of 37 HPV types. The HPV-positive rate was 57.6% in parotid gland tumor paraffin-embedded tissue specimens, whereas, the normal control group was negative for HPV. The HPV-positive rate was 59.6% in parotid gland benign tumor tissues and 42.9% in parotid malignant tissues. HPV infection in parotid gland tumors was dominated by the high-risk subtypes (80.7%), which mainly consisted of HPV 16, 18 and 52 (61.4%). In addition, parotid gland tumor tissues were found to be infected by multiple or single types of HPV, but were predominantly infected by mixed HPV types. In this study, we found that the occurrence of parotid gland tumor is correlated with HPV infection.
Collapse
Affiliation(s)
- Wei-Qiang Teng
- Graduate College, Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China
| | - Xiao-Ping Chen
- Department of Otolaryngology, Shanghai Pudong New Area Gongli Hospital, Shanghai 200135, P.R. China
| | - Xiao-Cheng Xue
- Graduate College, Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China
| | - Yi Zhang
- Department of Otolaryngology, Shanghai Pudong New Area Gongli Hospital, Shanghai 200135, P.R. China
| | - Xue-Jun Tan
- Department of Otolaryngology, Wanzhou Shanghai Hospital, Chongqing 404100, P.R. China
| | - Guangbin Sun
- Department of Otolaryngology, Shanghai Pudong New Area Gongli Hospital, Shanghai 200135, P.R. China
| | - Yan Wang
- Graduate College, Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China
| | - Li Wang
- Department of Otolaryngology, Shanghai Pudong New Area Gongli Hospital, Shanghai 200135, P.R. China
| |
Collapse
|
45
|
Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, Rosenberg PS, Bray F, Gillison ML. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 2013; 31:4550-9. [PMID: 24248688 DOI: 10.1200/jco.2013.50.3870] [Citation(s) in RCA: 982] [Impact Index Per Article: 81.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
PURPOSE Human papillomavirus (HPV) has been identified as the cause of the increasing oropharyngeal cancer (OPC) incidence in some countries. To investigate whether this represents a global phenomenon, we evaluated incidence trends for OPCs and oral cavity cancers (OCCs) in 23 countries across four continents. METHODS We used data from the Cancer Incidence in Five Continents database Volumes VI to IX (years 1983 to 2002). Using age-period-cohort modeling, incidence trends for OPCs were compared with those of OCCs and lung cancers to delineate the potential role of HPV vis-à-vis smoking on incidence trends. Analyses were country specific and sex specific. RESULTS OPC incidence significantly increased during 1983 to 2002 predominantly in economically developed countries. Among men, OPC incidence significantly increased in the United States, Australia, Canada, Japan, and Slovakia, despite nonsignificant or significantly decreasing incidence of OCCs. In contrast, among women, in all countries with increasing OPC incidence (Denmark, Estonia, France, the Netherlands, Poland, Slovakia, Switzerland, and United Kingdom), there was a concomitant increase in incidence of OCCs. Although increasing OPC incidence among men was accompanied by decreasing lung cancer incidence, increasing incidence among women was generally accompanied by increasing lung cancer incidence. The magnitude of increase in OPC incidence among men was significantly higher at younger ages (< 60 years) than older ages in the United States, Australia, Canada, Slovakia, Denmark, and United Kingdom. CONCLUSION OPC incidence significantly increased during 1983 to 2002 predominantly in developed countries and at younger ages. These results underscore a potential role for HPV infection on increasing OPC incidence, particularly among men.
Collapse
Affiliation(s)
- Anil K Chaturvedi
- Anil K. Chaturvedi, William F. Anderson, and Philip S. Rosenberg, National Cancer Institute, Rockville, MD; Maura L. Gillison, The Ohio State University, Columbus, OH; Joannie Lortet-Tieulent, Jacques Ferlay, Silvia Franceschi, and Freddie Bray, International Agency for Research on Cancer; and Maria Paula Curado, International Prevention Research Institute, Lyon, France
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Carrière GM, Sanmartin C, Bryant H, Lockwood G. Rates of cancer incidence across terciles of the foreign-born population in Canada from 2001-2006. CANADIAN JOURNAL OF PUBLIC HEALTH = REVUE CANADIENNE DE SANTE PUBLIQUE 2013; 104:e443-9. [PMID: 24495818 PMCID: PMC6973830 DOI: 10.17269/cjph.104.3884] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/20/2013] [Revised: 10/25/2013] [Accepted: 10/29/2013] [Indexed: 12/18/2022]
Abstract
OBJECTIVES To address the issue of comparative risk of cancer in Canada's immigrant population, an area-based methodology was applied to examine whether or not estimated cancer incidence rates among individuals living in given areas vary systematically according to the concentration of foreign-born individuals living in the same area. This method provides an alternative, accessible surveillance method in the absence of linked individual-level information to extend the work of others by providing both national and subnational standardized, hence comparable, results to address this issue. METHODS Canadian Cancer Registry data (2001 to 2006) and 2006 Census data provided dissemination area information regarding the concentration of the foreign-born population and population estimates for rate denominators. Cancer (all cause and cause-specific) incidence rate ratios (age-standardized and by age/sex) were calculated by foreign-born concentration areas at both national and regional levels. RESULTS An inverse gradient was identified between cancer incidence rates and area concentration of foreign-born, with the all-sites cancer rate ranging from a low of 388 per 100,000 among individuals living in areas with a high concentration of foreign-born to a high of 493 per 100,000 among individuals living in areas with a low concentration of foreign-born. This pattern occurred nationally for lung, colorectal, prostate and female breast cancers. However, for liver, nasopharynx, and thyroid cancers, higher cancer rates were observed in areas with a higher versus lower concentration of foreign-born populations. CONCLUSION The study findings provide suggestive evidence of decreased cancer risk among foreign-born populations for most cancers except nasopharynx, liver and thyroid for which risks were higher. The results of this study demonstrate the value of ecological-based methods for disease surveillance in the absence of individual-level information on immigrant status in the national cancer registry.
Collapse
|
47
|
Epidemiology of oral human papillomavirus infection. Oral Oncol 2013; 50:364-9. [PMID: 24080455 DOI: 10.1016/j.oraloncology.2013.09.003] [Citation(s) in RCA: 99] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2013] [Revised: 07/18/2013] [Accepted: 09/04/2013] [Indexed: 01/17/2023]
Abstract
OBJECTIVE To describe what is known about the epidemiology of oral human papillomavirus (HPV) infection. METHODS In this article we review current data on HPV prevalence, natural history, mode of acquisition, and risk factors for oral HPV infection. RESULTS & CONCLUSION Over the past several years new studies have informed our understanding of oral HPV infection. These data suggest oral HPV prevalence is higher in men than women and support the sexual transmission of HPV to the mouth by oral sex. Data is emerging suggesting that most oral HPV infections usually clear within a year on and describing risk factors for prevalent and persistent infection. Recent data support likely efficacy of the HPV vaccine for oral HPV, suggesting vaccination may reduce risk of HPV-related oropharyngeal cancer.
Collapse
|
48
|
Nichols AC, Palma DA, Dhaliwal SS, Tan S, Theuer J, Chow W, Rajakumar C, Um S, Mundi N, Berk S, Zhou R, Basmaji J, Rizzo G, Franklin JH, Fung K, Kwan K, Wehrli B, Salvadori MI, Winquist E, Ernst S, Kuruvilla S, Read N, Venkatesan V, Todorovic B, Hammond JA, Koropatnick J, Mymryk JS, Yoo J, Barrett JW. The epidemic of human papillomavirus and oropharyngeal cancer in a Canadian population. ACTA ACUST UNITED AC 2013; 20:212-9. [PMID: 23904762 DOI: 10.3747/co.20.1375] [Citation(s) in RCA: 82] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
BACKGROUND Sexually transmitted infection with the human papillomavirus (hpv) is responsible for a significant burden of human cancers involving the cervix, anogenital tract, and oropharynx. Studies in the United States and Europe have demonstrated an alarming increase in the frequency of hpv-positive oropharyngeal cancer, but the same direct evidence does not exist in Canada. METHODS Using the London Health Sciences Centre pathology database, we identified tonsillar cancers diagnosed between 1993 and 2011. Real-time polymerase chain reaction was then used on pre-treatment primary-site biopsy samples to test for dna from the high-risk hpv types 16 and 18. The study cohort was divided into three time periods: 1993-1999, 2000-2005, and 2006-2011. RESULTS Of 160 tumour samples identified, 91 (57%) were positive for hpv 16. The total number of tonsillar cancers significantly increased from 1993-1999 to 2006-2011 (32 vs. 68), and the proportion of cases that were hpv-positive substantially increased (25% vs. 62%, p < 0.002). Those changes were associated with a marked improvement in 5-year overall survival (39% in 1993-1999 vs. 84% in 2006-2011, p < 0.001). When all factors were included in a multivariable model, only hpv status predicted treatment outcome. INTERPRETATION The present study is the first to provide direct evidence that hpv-related oropharyngeal cancer is increasing in incidence in a Canadian population. Given the long lag time between hpv infection and clinically apparent malignancy, oropharyngeal cancer will be a significant clinical problem for the foreseeable future despite vaccination efforts.
Collapse
Affiliation(s)
- A C Nichols
- Department of Otolaryngology Head and Neck Surgery, The University of Western Ontario, London, ON. ; London Regional Cancer Program, London, ON. ; Lawson Health Research Institute, London, ON. ; Department of Oncology, The University of Western Ontario, London, ON. ; Department of Pathology, The University of Western Ontario, London, ON
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Ariyawardana A, Johnson NW. Trends of lip, oral cavity and oropharyngeal cancers in Australia 1982-2008: overall good news but with rising rates in the oropharynx. BMC Cancer 2013; 13:333. [PMID: 23829309 PMCID: PMC3716721 DOI: 10.1186/1471-2407-13-333] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2012] [Accepted: 06/24/2013] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Considerable global variation in the incidence of lip, of oral cavity and of pharyngeal cancers exists. Whilst this reflects regional or population differences in risk, interpretation is uncertain due to heterogeneity of definitions of sites and of sub-sites within this anatomically diverse region. For Australia, limited data on sub-sites have been published. This study examines age-standardised incidence trends and demography from 1982 to 2008, the latest data available. METHODS Numbers of cases within ICD10:C00-C14 were obtained from the Australian Institute of Health and Welfare, recorded by sex, age, and sub-site. Raw data were re-analysed to calculate crude, age-specific and age-standardised incidence using Segi's world-standard population. Time-trends were analysed using Joinpoint regression. RESULTS Lip, Oral Cavity and Pharyngeal (excluding nasopharynx) cancers, considered together, show a biphasic trend: in men rising 0.9% pa from 1982 to 1992, and declining 1.6% pa between 1992 and 2008. For females: rises of 2.0% pa 1982-1997; declines of 2.8% pa 1997-2008. Lip cancer is declining especially significantly. When the Oropharynx is considered separately, steadily increasing trends of 1.2% pa for men and 0.8% pa for women were observed from 1982 to 2008. CONCLUSIONS Although overall rates of lip/oral/oropharyngeal cancer are declining in Australia, these are still high. This study revealed steady increases in cancers of the oropharynx, beginning in the late 1990s. Continued efforts to reduce the burden of these cancers are needed, focused on reduction of the traditional risk factors of alcohol and tobacco, and with special emphasis on the possible role of human papillomavirus and sexual hygiene for cancers of the oropharynx.
Collapse
Affiliation(s)
- Anura Ariyawardana
- Population and Social Health Research Programme (Population Oral Health Group), Griffith Health Institute, Gold Coast Campus, Griffith University, Gold Coast, QLD 4222, Australia
| | | |
Collapse
|
50
|
Betiol J, Villa LL, Sichero L. Impact of HPV infection on the development of head and neck cancer. Braz J Med Biol Res 2013; 46:217-26. [PMID: 23532264 PMCID: PMC3854371 DOI: 10.1590/1414-431x20132703] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2012] [Accepted: 01/03/2013] [Indexed: 01/20/2023] Open
Abstract
Human papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC)
is considered to be a distinct clinical entity with better prognosis than the
classical tobacco- and alcohol-associated tumors. The increasing incidence of
this neoplasia during the last decades highlights the need to better understand
the role of HPV in the development of these cancers. Although the proportion of
HNSCC attributed to HPV varies considerably according to anatomical site,
overall approximately 25% of all HNSCC are HPV-DNA positive, and HPV-16 is by
far the most prevalent type. In this review we discuss the existing evidence for
a causal association between HPV infection and HNSCC at diverse anatomical head
and neck subsites.
Collapse
Affiliation(s)
- J Betiol
- Laboratório de Biologia Molecular, Centro de Investigação Translacional em Oncologia, Instituto do Câncer do Estado de São Paulo,São Paulo, SP, Brasil
| | | | | |
Collapse
|